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                                       Abstract 
 Stem cells hold great potential for the regenerative medicine and 
tissue engineering. Controlling the fate of stem cell in a reliable method 
still remains a problem. The strategies for directing the fate of stem cells 
include biophysical cues (e.g. matrix stiffness, topography, and 
extracellular forces), biochemical cues (e.g. growth factors, cytokines and 
chemokines) and cellular reprogramming (e.g. gene delivery). Controlled 
delivery of specific genes, such as transcription factor encoding genes, to 
stem cells is a promising strategy for stem-cell based therapy.  
           Gene delivery methods include two major categories: viral vectors 
and non-viral vectors. Non-viral gene delivery vectors hold great promise 
for gene therapy due to the safety concerns with viral vectors. However, 
the application of non-viral vectors is hindered by their low transfection 
efficiency. Herein, in order to tackle this challenge, we endeavored to 
develop non-viral vectors with efficient gene delivery and low toxicity to 
hard-to-transfect MSCs.  
          First, we focused on the identification and characterization of novel 
MSCs-targeting peptides using phage libraries. A peptide (VTAMEPGQ) 
that can home to rat mesenchymal stem cells (rMSCs) was identified. This 
VTAMEPGQ peptide demonstrated high affinity and specificity to rMSCs. 
xxiii 
When integrated into liposome protamine/DNA lipoplex (LPD) system, 
the peptide significantly enhanced gene transfection efficiency to rMSCs.  
           Second, we focused on developing efficiently and chemically-
defined LPD-based gene delivery system to rMSCs. We employed three-
folds reiterated VTAMEPGQ peptides, nuclear localization signal and 
liposome/protamine complex to delivery vascular endothelial growth 
factor (VEGF) reporter gene to rMSCs. The developed LPD gene delivery 
complex demonstrated high transfection efficiency and long-lasting gene 
expression profile.  
         Third, we developed Glutathione (GSH) cleavable magnetic/silica 
nanoclusters integrating MSC-homing major coat protein (pVIII) for 
targeted gene delivery. pVIII proteins were purified from the 
VTAMEPGQ-sequence bearing phage identified by phage display 
technique. The intracellular GSH is responsible for cleaving the S-S bond 
to dissociate the nanoclusters to release DNA. The as-synthesized gene 
delivery complex also showed satisfactory gene transfection result to 
rMSCs.  
          Finally, we studied the role of cell-binding peptides in directing the 
stem cell differentiation. We take advantage of the three peptides, which 
are selected by phage display and show different binding affinities against 
MSCs, to investigate the osteogenic differentiation of MSCs. Surprisingly, 
xxiv 
we discovered that the peptide (VTAMEPGQ) with the highest MSC-
binding affinity induced the osteogenic differentiation of MSCs most 
efficiently. We propose that the MSC-binding peptides may bind to the 




                         Chapter 1    Introduction 
1.1 Stem cell 
  Stem cells hold promising potential for the regeneration of injured, 
diseased and aged tissues. There are three main types of stem cells: 
embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and 
adult stem cells (ASCs). Embryonic stem cells, which are derived from 
inner cell mass of blastocysts, could differentiate to generate all three 
embryonic germ layers, that is, ectoderm, endoderm, and mesoderm1,2. 
Induced pluripotent stem cells, which have all the characteristics of 
embryonic stem cells, were first developed by introducing four defined 
factors into somatic fibroblast cells3. ESCs and iPSCs have unlimited 
self-renewal potential in culture, but the lack of reliable methods to 
pattern these cells into a tissue specific lineage limits their uses in clinics. 
iPSCs are extremely advantageous because they show high immune 
compatibility and avoid ethical issues faced by ESCs. Adult stem cells 
(for example mesenchymal stem cells) lack the plasticity of ESCs and 





1.1.1 Stem cell niche 
   In the body, adult stem cells reside in a special microenvironment 
termed the “niche,” which supports and regulates stem cells to maintain 
tissue homeostasis. Extrinsic signals, including secreted factors, cell-cell 
interactions and ECM, regulate stem cell fate collectively. Transforming 
growth factor beta (TGF-β) superfamily, including TGF-β proteins, 
growth differentiation factors (GDFs) and bone morphogenetic proteins 
(BMPs), regulates various biological effects by binding to targeting cell 
surface receptors4. For example, bone morphogenetic protein 2 (BMP2) 
was demonstrated to induce the basic helix-loop-helix protein MASH1 
and neurogenesis in neural crest stem cells.5.   
Various intrinsic factors also contribute to stem cell self-renewal 
and differentiation. Cell fate in development is delicately regulated by 
transcription factors that act as molecular switches to turn on or inactivate 
specific gene expression6. The POU domain transcription factor Oct3/4 is 
essential for the pluripotency in embryo and ESCs in vitro7. Multipotent 
cell lineages in early development are governed by SRY (sex determining 
region Y)-related HMG (high-mobility group)-box transcription factor 
Sox28,9. Also, The homeoprotein Nanog a critical factor underlying 
pluripotency in both inner cell mass and ESCs10. Oct4-Sox2-Nanog 
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network together maintains cell pluripotency while repressing genes that 
induce differentiation11. By introducing defined factors including Oct3/4  
and Sox 2, mouse and human somatic cells can be reprogrammed to 
ESCs-like  iPSCs3,12 . 
The niche concept was first proposed by Schofield in 197813. Stem 
cells in the niche are exposed to complex biochemical mixtures of soluble 
factors including cytokines, chemokines, and growth factors, as well as 
insoluble factors including extracellular matrix (ECM) and 
transmembrane receptors14. Upon injury or disease, stem cells in the 
niche are induced to proliferate and differentiate into target cell types and 
restore damaged tissue. Niche system also regulates stem cells through 
biophysical cues including matrix topography, density and mechanical 
properties15,16. Furthermore, the niche prevents tumorigenesis by 
controlling stem cells in the arrested state and maintaining the balance 
between self-renewal and differentiation17.  
The niche hypothesis had been verified by a variety of co-culture 
and transplantation experiments18-21. In contrast to the fruitful research on 
invertebrate niches, the relative vastness of mammalian tissues and the 
complicated anatomic structure make it much more difficult to 
characterize individual stem cells in vivo17,22. Among mammalian tissues, 
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epithelial stem cells reside in the bulge of hair follicles of the skin23,24. 
Neural stem cells (NSCs) reside in the subventricular zone (SVZ) of 
lateral ventricle in the brain25. Muscle stem cells reside among satellite 
cells beneath the basal lamina of myofibers21. Hematopoietic stem cells 
reside in multiple niches, including bone marrow and sinusoidal 
endothelium in diverse tissues26. MSCs also reside within bone marrow.27   
   Stem cells are defined by their ability to self-renew and 
differentiate into different mature cell types. Therefore, stem cells hold 
great promise for regenerative medicine therapies. However, the stem cell 
therapy is hindered by limitations including immuno-incompatibility, 
teratoma risk and so on. Overcoming the obstacles requires designing 
biomaterials that better mimic stem cell niche where stem cells reside in 
inside biological body. Ideally, an artificial niche (Figure 1.1) would 
include cell-extracellular matrix (ECM) interactions, cell-cell interactions, 
soluble biochemical factors and biophysical cues28. Although remarkable 
accomplishments had been made towards these needs, great efforts still 




Figure 1.1  Schematic illustration of artificial stem cell niche.  An ideal 
niche includes cell-tethered ECM molecules (collagen, laminin, 
fibronectin and so on), molecules for cell-cell interactions (integrins, 
cadherins, selectins and so on), and cell-soluble factors (growth factors, 
cytokines, chemokines and so on).  (Figure adapted with permission from 
reference 28) 
1.1.2 Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) have the capacity to differentiate 
into cells of mesodermal lineages, including osteogenic, chondrogenic, 
myogenic and adipogenic lineages. This differentiation capacity makes 
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the use of MSCs an attractive treatment for tissue regeneration and 
engineering. Furthermore, they are relatively easy to isolate, manipulate 
and culture, show significant expansion capability. These characteristics 
make MSCs excellent candidates for the regenerative medicine. 
   Friedenstein et al found that the cells isolated from bone marrow 
can differentiate into fibroblast-like mesenchymal stem cells29,30. They 
first isolated the whole bone marrow from mouse and cultured in plastic 
dishes. Then the non-adherent cells (hematopoietic cells) are discarded 
after 4 hours. The remaining adherent cells were initially heterogeneous 
in morphology, while most of the cells were spindle-shaped. The 
adherent cells remained slow growth for 2-4 days and then the growth 
rate increased rapidly. After several passages, the cells became more 
homogeneously and are fibroblast-like. Their study also found that these 
cells could differentiate into colonies similar to bone or cartilage deposits. 
Other groups continued to explore the characterization of bone-marrow 
developed adherent cells from Friedenstein’s method and they 
demonstrated that the cells were multipotential and could differentiate 
into osteoblasts(bone cells), chondrocytes (cartilage cells), adipocytes (fat 
cells), and even myoblasts (muscle cells)31,32. These cells were named 
mesenchymal stem cells (MSCs), because their potential to differentiate 
into mesenchymal-type cells. Besides bone marrow, MSCs have also 
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been isolated from various locations including adipose tissue, fetal blood, 
liver, amniotic fluid, etc33,34.  
  Osteoblasts differentiation of MSCs can be induced by 
biochemical cues including ascorbic acid, dexamethasone and beta-
glycerophosphate for around 2 weeks. The osteogenic induced MSCs can 
form nodules and alkaline phosphatase activity increases35. Also, the 
calcium deposit can be observed over time and these calcium nodules will 
be stained positively by alizarin red. To induce the adipogenic 
differentiation, MSCs will be treated with insulin, isobutyl methyl 
xanthine, dexamethasone, and indomethacin. The differentiated cells 
show enrichment of lipid rich vacuoles. Adipogenic markers such as 
lipoprotein lipase, and the fatty acid-binding protein aP2 can be detected. 
Oil red O staining is used to evaluate the Accumulation of lipid in cell 
vacuoles. For chondrogenic differentiation, MSCs are exposed to 
transforming growth factor-beta36. The differentiated MSCs demonstrate 
strong staining by toluidine blue, which indicates glycosaminoglycans 
accumulation within the extracellular matrix. To promote myoblastic 
differentiation,  5-azacytidine and amphotericin B were used to treat 
MSCs37. Study also found that MSCs can be induced to be neuron-
lineage specific efficiently38. The MSCs were gene transfected with 
Notch intracellular domain and then exposed with basic fibroblast growth 
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factor, forskolin and ciliary neurotrophic factor. Neural stem cells 
specific markers were observed after gene transfection. Induced neuronal 
cells were also verified after growth factor introduction.  
   Overall, MSCs are multipotent and have capacity to differentiate 
into specialized cell types. MSCs can go through numerous cell divisions 
while maintaining the potency. Also, MSCs can be easily obtained from 
bone marrow or adipose tissue and can be easily expanded in vitro. All 
these advantages make MSCs attractive candidate for regenerative 
medicine and biomedical engineering.  
1.2 Gene delivery to stem cells 
Gene therapy is the treatment of disease by delivery of genetic 
information into specific target cells39. The completion of Human 
Genome Project and the advances in biotechnology as well as molecular 
biology has contributed to the discovery of numerous disease-related 
genes.  Gene therapy can be realized by direct replacement of abnormal 
genes to treat diseases such as muscular dystrophy40 or cystic fibrosis41, 
etc. By delivering therapeutic genes to alter the gene expression of 
current genomes, diseases such as neurological42,43, cardiovascular44 or 
cancer45 can be treated.  
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  Due to the great therapeutic potential the gene therapy could bring, 
gene therapy has been heavily investigated for the last decade.  In 2000, 
by treatment of two infants with severe combined immunodeficiency-X1 
disease, Cavazzana-Calvo et al. reported the first successful clinical trial 
of gene therapy46.  
1.2.1 Gene therapy strategies 
Overall there are two types of gene therapy strategies: direct gene 
delivery and cell-based gene delivery47. An ideal gene therapy method 
should present following features: efficient encapsulation and protection 
of DNA, high transfection efficiency, minimum non-specific interactions 
with circulation system such as blood, non-immunogenic and nontoxic, 
etc.  
The direct gene delivery indicates delivering therapeutic genes 
containing vectors directly to the location of injury48.  Under this 
condition, a scaffold will be used for controlled release or direct injection 
of gene-containing vector to the target organ. However, the cells adjacent 
to the targeting area may also be transfected, which lowers the overall 
transfection efficiency.  To tackle this problem, a transfection system 
with targeting functionality may be used. Another problem with this 
strategy is: some vectors can only transfect cells that are actively dividing. 
10 
 
It is during the cell dividing phase that the cell nucleus member 
disappears and the genes have the opportunity to integrate with the cell 
genome. For instance, heart or brain is mostly composed of non-dividing 
cells. It would be difficult to use vectors directly to transfect these organs. 
This problem limits the application of direct gene delivery. 
   For cell-based gene delivery, most often a type of stem cell will 
be used as target cell. The gene-containing vectors are introduced into the 
target cells in vitro. During the in vitro process the transfected cells can 
be cultured in dishes or already in a three-dimensional (3D) environment. 
Then the transfected cells are allowed to proliferate to enough amounts 
and finally introduced to injury sites of patients. Study showed that stem 
cell, such as MSCs, can be used for cell-based gene delivery and thus 
serve as invaluable source for understanding the molecular mechanisms 
underlying tissue/organ regeneration and repair49,50.  
1.2.2 Gene delivery methods 
  Broadly, gene delivery methods include two major categories: 
viral vectors and non-viral vectors.  
  The typical method to deliver a therapeutic gene into cells 
involves the use of viral vectors, such as retrovirus, adenovirus, lentivirus 
(for example, HIV), adeno-associated virus, etc. The virus in nature, for 
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the purpose of self-replication, have developed skill to efficiently enter 
target cell, transport to the cell nucleus and promote expression of the 
virus genome. The virus gene delivery is termed “infection”. Viruses 
have evolved so sophisticated over nature’s selection as gene-delivery 
vectors, the recombinant viral vectors are essentially very efficient to 
allow stable gene expression. As a result, majority of gene-therapy 
research reported in the literature and clinical trials have used viral 
vectors as subjects51.  
  However, Due to the inherent problem such as immune responses 
induction and oncogenic risk, the viral gene delivery application is 
hindered52,53. Moreover, the viral vector’s packaging capacity of foreign 
DNA is limited and their large-scale production is onerous. There is also 
possibility that the viral vector may revert to a wild-type, which is 
pathogenic to host system. All these facts necessitate the development of 
alternative non-viral gene transfection systems.  
   Non-viral vectors give rise to improved safety, higher flexibility 
and more facile scalability. Ideal non-viral vectors can electrostatically 
bind gene into compact nanometer size particles and protect genes from 
degradation, show low immunogenicity and low transmission disease 
risk52,53. The extensively studied non-viral vectors include cationic 
polymers and lipids. They are also known as polyplexes and lipoplexes, 
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respectively. However, the study of non-viral vectors for gene delivery 
present problem comparing with viral vectors, such as lower transfection 
efficiency54, unpredictability and transfection efficiency strongly depend 
on cell type, in vivo instability and tend to be degraded or removed by 
host circulation system and possible high toxicity, etc. For instance, 
primary cells, e.g. MSCs, are hard to transfection by non-viral vectors55.  
Non-viral delivery method can only delivery genes passively to 
cells during cell division phase when cell nuclear membrane transiently 
disappeared. Thus, non-viral delivery strictly dependent on cell division 
process to facilitate DNA delivery into cell nucleus. Since most primary 
cells divide quite slowly or do not divide at all, it is very difficult to 
transfect primary cells using non-viral method.  
   Cationic lipids are the most extensively studied non-viral vectors 
due to their high transfection efficiency. The first reported use of cationic 
lipids for gene delivery is by Felgner in 198756. Cationic lipids can self-
assemble into liposomes by having non-polar tails and positive polar 
heads57. The positively charged liposome can bind to anionic DNA to 
form “lipoplexes”.  The DNA can be either bound to liposome surface or 
be encapsulated in the internal aqueous phase. After endocytosis into 
cells, the lipoplex will disrupt the endosomal membrane to release DNA 
into cell cytoplasm58.  Commercially available liposome-based 
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transfection vectors, such as Lipofectamine® 2000, FuGENE™ 6 and 
Effectene™ have been developed for cell gene transfection59-62. These 
commercially available products are also often used as reference vectors 
as comparison to newly developed gene delivery materials. 'Lipofection' 
has also been widely used in in vivo gene delivery studies as well as 
many gene-therapy clinical trials. However, liposome-based gene 
delivery method suffers limitations, including cellular toxicity and 
particle stability upon systemic administration. 
Cationic polymers are versatile molecules that were studied as gene 
delivery vectors63,64. The polymers vectors can include linear, branched 
and dendritic structures. Variations in polymer design comprise 
molecular weight, chemical composition, degree of branching and density. 
Cationic polymers usually contain high level of DNA-binding moieties 
functional groups (e.g. primary, secondary, tertiary and quaternary 
amines) and other positively charged groups such as amidines. Due to the 
flexibility of polymer chemistries, it is possible to offer multiple-
functionality for efficient gene delivery while maintaining stable 
formulation, biocompatibility and easy production. The cationic polymers 
can interact with negatively charged DNA to from polyplexes.  
“Polyfection” is termed as gene transfection mediated by polymers. 
Polyethylenimine (PEI), a type of cationic polymers, is often used as a 
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reference in gene transfection studies. PEI can be either linear or 
branched. After entering cell,  PEI escapes from endosomes through a 
“proton-sponge” mechanism65. PEI over a wide range of molecular 
weights had been studied as a gene delivery vectors. Molecular weights 
between 12-70 kDa demonstrated the highest transfection efficiency66,67. 
Ahn et al  used pDNA/PEI polyplexes and reported a 10% transfection 
efficiency to bone marrow derived MSCs68. The study also showed that 
optimal transfection efficiency was obtained at an N/P ratio (N is moles 
of primary amines in the PEI; P is moles of phosphate groups in the DNA 
backbone) of 16.  
1.2.3 Gene delivery barriers 
1.2.3.1 DNA encapsulation 
Naked DNA delivered to cells is degraded by DNase within 
minutes. Thus a vector is necessary to encapsulate DNA to protect DNA 
from nucleolytic enzyme degradation. Hosam et al showed that DNA 
encapsulated in polyamidoamine dendrimers were stable for hours69.  The 
study showed that the protection is related to the structural morphology 
of the formed dendrimer-DNA complex, which is dependent on time 
allowed for complex formation and the dendrimer loading. Through 
electrostatic interactions between the positive charges on vector and the 
15 
 
negative charges on DNA backbone (phosphates groups), gene delivery 
carriers interact and condense DNA into compact particles (Figure 1.2). It 
is an entropically driven process and the mixed DNA and vector should 
form complex spontaneously. It is noticeable that researchers need to 
make a balance between strong binding to encapsulate DNA and efficient 






Figure 1.2 DNA-vector complexes are formed by electrostatic interactions 
between polycations and DNA. (Figure adapted with permission from 
reference 39). When aqueous solutions of a polycation and DNA are 
mixed, polyplexes form spontaneously. The interaction is entropically 
driven. For gene delivery, an excess of polycation is typically used, which 
generates particles with a positive surface charge.  
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  1.2.3.2 In vivo stability 
      It is crucial that the DNA-vector complex is stable in vivo after 
injection. Neutral complexes in physiological conditions quickly form 
large aggregates due to the hydrophobic effect. Thus it is an ineffective 
gene-delivery method and could even be toxic. In comparison, positively 
charged particles can remain relative stable in solution. Higher positively 
charged particles can also absorb serum albumin as well as more 
negatively charged proteins to form larger aggregates. The large 
aggregates can bind to cell membrane and disrupt the membrane to 
induce toxicity. It also might lead to rapid clearance by phagocytic cells 
and the reticuloendothelial system71.  When the vector particles are 
conjugated with hydrophilic polymers such as polyethylene glycol (PEG), 
the particles can resist protein or salt induced interference72,73. It is 
presumed that the enhanced stability is due to the steric effects that lead 
to diminished particle–protein and particle–particle interactions. 
 1.2.3.3 Cell-targeting vectors 
The most challenging question in gene or drug delivery system is 
efficient targeted delivery of gene materials, otherwise the majority of the 
effective agents are wasted during the pathway. Generally, targeting 
moieties are conjugated to gene delivery vectors to provide cell-targeting 
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functionality. The cell specific vectors can target specific cell receptors 
and enter cell via receptor-mediated endocytosis. Study reported that 
galactosylated vectors can specifically target hepatocyte and enhanced 
the transfection efficiency74,75 . Folate-bearing vectors were used to 
transfect genes into receptor-bearing HeLa and IGROV cell lines76.  
Other specific agents, including antibodies77, epidermal growth factor78, 
RGD sequence79 targeting integrin were also used for cell specific gene 
delivery. Various conjugation methods have been used to bind targeting 
motifs to vectors, such as disulfide bond or biotin–streptavidin interaction.  
 1.2.3.4 Endocytosis and Endosome escape. 
The vector-DNA particles typically are internalized by endocytosis 
to be encapsulated in endosomes (Figure 1.3). Endosomes are the 
membrane "bubbles" that originates from the cell plasma membrane. The 
particles can be fused to lysosomes, the acidic cell organelle filled with 
hydrolytic enzymes capable of degrading all kinds of biomolecules80. The 
particles need to escape from these vesicles into the cytoplasm and be 
trafficked into cell nucleus for gene expression.  The particles without 
targeting motif bind electrostatically to the cell membrane and are 
typically internalized via adsorptive pinocytosis81. The particles with 
targeting motifs are often internalized a by receptor-mediated endocytosis 
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mechanism. The particles in the early endosome are then transformed 
into late endosomes. Due to ATPase proton-pump activated proton influx, 
late endosomes rapidly acidify to pH around 5–6. The late endosomes 
subsequently fused to lysosomes, with further activated proton influx to 
lower the pH to approximate 4.5. Most DNA-bearing particles are 
trapped in these cell compartments and are degraded and recycled. The 
optimal gene delivery vectors need to escapes from these vesicles to get 
into cell nucleus.  
 
Figure 1.3  Barriers to intracellular trafficking of polyplexes.  Polyplexes 
needs to attach to cell surface and then enter cell by endocytosis, escape 
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from endolysosomes, move through the cytoplasm toward the nucleus and 
cross the nuclear membrane. Alternative pathways exist for several of 
these steps. (Figure adapted with permission from reference 39). 
    One strategy for escape from the cellular compartment is the 
proton-sponge mechanism65. Polymers such as polyethylenimine 
(PEI)82,83 and polyamidoamine (PAMAM) dendrimers contain a high 
density of primary, secondary and tertiary amines. These amine groups 
can accept the protons pumped into cell vesicles to prevent pH decrease. 
As a result, more protons are pumped in for the purpose of reaching the 
desired acidic pH. The accumulation of protons in the vesicle needs to be 
balanced by another influx of negative charged ions, such as chloride. 
The increased ion concentration inside the vesicle will induce more influx 
of water molecules and ultimately results in osmotic breakdown of 
endosome vesicle to release the DNA into the cytoplasm. 
1.2.3.5 Nucleus transport 
After particles bearing DNA escape from endosome, they need to 
migrate through the cytoplasm to the cell nucleus for gene expression. 
However, the cytoplasm contains organelles, cellular proteins and 
microtubules, etc. All these obstacles may hinder particle movement. In 
addition, the presence of cytosolic nucleases in the cytoplasm would 
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degrade all unprotected DNA84, which exert another barrier for successful 
gene transfection.  
The cell nucleus is protected by a double-bilayer membrane which 
tightly regulates the transport of specific type of biomolecules. Virus-
based vectors have evolved to take advantage of cell-nuclear import 
machinery to transport vectors to the cell nucleus85. However, it is a 
formidable obstacle for non-viral vectors to transport through cell nuclear 
membrane of non-dividing cells, as non-viral vectors don’t have the 
capacity to utilize cell nuclear import machinery. To overcome this 
obstacle, nuclear localization signal (NLS) peptides could be used to 
facilitate the transport of non-viral vectors into cell nucleus. The NLS 
consists of sequences of positively-charged lysine or arginine amino 
acids86. The NLS is recognized by importin to initiate cell nucleus 
translocation. Maria et al reported that transfection efficiency was 
enhanced by 10- to 1,000-fold to different cell types after the single 
nuclear localization signal peptide (PKKKRKVEDPYC) was 
incorporated in gene delivery87.   
1.3 Designing biomaterials to regulate stem cell fate. 
            Two-dimensional (2D) systems are advantageous to identify and 
characterize the effects of individual niche factors on stem cell fate.  In 
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vitro, stem cell research is performed frequently with cells cultured on flat 
substrates coated with collagen, laminin or feeder-cell layers. The effect of 
soluble or tethered ECM molecules had been explored both individually 
and collectively. In one example, human neural precursor cells were 
exposed to a mixture of ECM components and other recombinant 
signaling molecules88. The study revealed that Wnt signaling and Notch 
signaling could synergistically maintain the cells in an undifferentiated 
state, whereas BMP 4 signaling could induce a differentiated phenotype 
characterized by co-expression of glial and neuronal markers. Diseased 
tissues are often related to altered organization of ECM components such 
as laminin, resulting in substantial changes to the stiffness of the matrix. 
Natural and synthetic materials can be engineered to be cell culture 
matrices with controlled stiffness. For example, mesenchymal stem cells 
(MSCs) were demonstrated to specify lineage and phenotypes with 
extreme sensitivity to matrix stiffness. Soft matrices induced neurogenic, 
stiffer matrices showed myogenic, and rigid matrices are proven 
osteogenic89.  
            In 2D scaffolds, cells are typically cultured on a flat surface at the 
basal side and liquid medium on the apical surface. In 3D scaffolds, stem 
cells can be encapsulated into a sophisticated microenvironment that is 
more comparable to cells grown in vivo. When cultured on 3D materials, 
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many aspects of cell behaviors, including adhesion, proliferation, 
migration and differentiation showed variability compared with cells 
cultured on 2D substrates. In general, biomaterials used for 3D scaffolds 
should have the following characteristics: biocompatibility, 
biodegradability, reproducibility, high porosity and high 
immunocompatibility90. Furthermore, it is also highly desirable that the 
scaffold has the ability to promote ECM secretion and to deliver bioactive 
signals. It is important that the 3D environment has interconnected pores, 
which facilitates the free flow of air and nutrients. In one example, Human 
embryonic stem cells (hESCs) were cultured in a three-dimensional 
porous natural polymer scaffold comprised of chitosan and alginate91. The 
results demonstrated biocompatibility and biodegradability of the polymer 
scaffold, and provide a strategy for the direct implantation of stem cell 
populated scaffolds. The physical barriers that impede cell proliferation, 
migration and morphogenesis should also be overcome14. One promising 
approach is to use polymer gels that contain chemically cross-linked 
substrates that are degradable when exposed to proteases secreted by cells. 
This feature allows a dynamic interplay between the cells and the scaffold, 
which would facilitate the infiltration of cells and thus the re-homogeneity 
of the matrices. For instance, matrix metalloproteinase (MMP) degradable 
hydrogels have been demonstrated to promote cell migration through 
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proteolytic degradation and to support cell growth both in vitro and in 
vivo92,93.  
            The different components that make up the ECM provide an 
insight for designing scaffolds based on protein and peptide biomaterials94. 
The proteins and protein derivatives play critical roles in vivo and thus 
make such materials attractive for tissue engineering applications. 
Furthermore, their natural origin means that these materials often contain 
motifs for cellular adhesion and tend to be biocompatible. Engineered 
protein and peptide materials can uniquely meet the desire for a bioactive 
scaffold that is versatile and tunable95. Protein and peptide material design 
offers advantages in structure, cellular interaction, cellular signaling and 
specific cell targeting and binding. Designing these protein biomaterials 
molecularly provides engineers flexibility and reproducibility. In addition, 
a protein or peptide molecule is composed of a polymer backbone made of 
amino acids, which are inherently biocompatible, biodegradable and 
bioactive. The amino acid sequences can be derived from natural protein, 
through high-throughput screening or computational design to obtain 
multi-functionalities. The intrinsic properties of proteins and peptides 
provide tunable mechanical, chemical, and biological functionalities in the 
design of biomaterials.   
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           Phage display technique provides a promising means for 
identifying novel peptide ligands against a variety of targets without prior 
knowledge about their molecular properties96. Homing peptide sequences 
with high specificity and affinity to cells or tissues have been successfully 
discovered by phage display technique97,98. It is plausible that targeting 
ligands that bind diverse classes of receptors could exert effects on cell 
growth and differentiation. To provide insight into such novel ligands, the 
Kiessling lab employed phage display to identify novel peptides that bind 
to embryonal carcinoma (EC) pluripotent cells99. When fused to self-
assembled monolayers (SAMs) of alkanethiols on gold, six selected 
peptides sequences mediated EC cell adhesion. Further study showed 
synthetic surfaces displaying phage-display derived peptides maintained 
the proliferation of undifferentiated human ESCs. When these cells were 
cultured on SAMs presenting the sequence LTTAPKLPKVTR or 
TVKHRPDALHPQ in culture medium, they showed pluripotency 
expression at levels similar to the cells on Matrigel. In another study, 
Caprini et al utilized phage display technique on murine NSCs and 
isolated a peptide, KLPGWSG, associated with stem cell maintenance and 
differentiation100. This study concluded that KLPGWSG peptide sequence 
and the functionalized self-assembling peptide Ac-KLP (KLPGWSG 
acetylated at the N-terminus) can be used in stem cell therapies for nerve 
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regeneration. The Bush lab showed a collagen sponge scaffold niche 
modified with peptides derived from in vivo phage biopanning promoted 
repair of bone defects, whereas the control scaffold without peptides was 
less effective101. Treatment of MSCs increased alkaline phosphatase 
activity, enhanced nodule formation by the MSCs, and up-regulated the 
expression of genes for osteocalcin, osterix, bone sialoprotein, and runx2. 
Further study demonstrated that MSCs treated with peptides in vitro 
differentiate towards osteogenesis and the collagen sponge niche modified 
with peptides promoted the repair of unicortical defects. All these studies 
indicate that the phage screening strategy is a promising avenue towards 








Chapter 2 Synergetic Targeted Delivery of Sleeping-Beauty 
Transposon System to Mesenchymal Stem Cells Using LPD 
Nanoparticles Modified with a Phage-Displayed Targeting 
Peptide 
2.1  Introduction 
For decades, the goal of gene therapy has been the development of 
an optimal gene delivery system. Foreign DNA must penetrate three 
cellular barriers, including cell membrane, nucleus trafficking, and 
chromosomal integration for successful gene expression. Basically, gene 
delivery to mammalian cells can be categorized into two main methods: 
viral and non-viral. Viral vectors efficiently deliver genes to target cells 
as a part of their natural ability.102 However, clinical outcomes in several 
gene therapy trials have served to highlight key problems of 
carcinomatous mutation in their therapeutic application.39,103 Non-viral 
vectors alternatives to viral vectors are often less effective because 
integration of single genes into chromosomes requires efficiently 
penetrating the above three barriers.104,105 
Transposable elements can be considered as natural, non-viral gene 
delivery vehicles capable of efficient genomic insertion. The plasmid-
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based transposon system of Sleeping Beauty (SB) combines the 
advantages of viruses and naked DNA molecules. In contrast to plasmid 
vectors, transposons can integrate into host chromosomes through a 
precise, recombinase-mediated mechanism, providing long-term 
expression of the gene of interest in cells. The advantages of transposons 
in comparison to viral systems include their simplicity and improved 
safety concerns. 
Phage display is a promising technique to find interacting peptide 
ligands to certain targets without any prior knowledge about their 
molecular properties.96 In vitro and in vivo phage display applications 
have been successfully conducted by a large number of research groups 
to identify homing peptide ligands targeting various cells or tissues.106,107 
In this work, a peptide was screened by phage display to increase the 
targeting delivery of transposon to rat mesenchymal stem cells (rMSCs). 
In order to overcome the nuclear membrane, a nuclear localization signal 
(NLS) was used to enhance nuclear translocation of gene materials.  
Mesenchymal stem cells (MSCs) have the capacity to differentiate 
into cells of mesodermal lineages, including osteogenic, chondrogenic, 
myogenic and adipogenic lineages. This differentiation capacity makes 
MSCs an attractive candidate for tissue regeneration and engineering. 
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Furthermore, MSCs are relatively easy to isolate, manipulate and culture. 
In addition, MSCs show significant expansion capability in vitro.108,109 
These characteristics make them attractive candidates for the delivery of 
exogenous genes. We suggested that a novel rMSC-homing peptide by 
phage display screening, in combination with NLS, could enable novel 
preparation of efficient gene carriers. The resultant nanoparticle complex 
could promote the delivery of transposon into rMSC specifically. The 
peptide of nuclear localization signal (NLS) is derived from the simian 
virus 40 large tumor antigen (DKKKRKV) which mediates binding of the 
karyophilic protein to importin α. And the NLS peptide was found vital in 
achieving the high levels of gene expression.87 In conclusion, we used 
phage display technique to identify an rMSC-homing peptide ligand and 
then integrated the identified homing peptide and the reported NLS into a 
peptide-combined liposome-based carrier for development of an effective 
transposon gene delivery system. 
2.2 Methods and experiments 
2.2.1 Plasmid Development  
The original SB transposon pT2/SVNeo and transposase pSB11 
were a gift from Dr. Perry B. Hackett (University of Minnesota). The 
neomycin resistance gene in pT2/SVNeo was converted into the EGFP 
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gene by restriction digestion with Bcl I and BstB I (New England Biolabs, 
Inc. MA, USA). The fragment excised by the two restriction enzymes 
from pT2/SVNeo plasmids was discarded and replaced by a PCR 
fragment of pEGFP-N1 with a similar restriction digestion. The sequence 
of primer 1 is GCGGTGATCATATGGTGAGCAAGGGC; the primer 2 
is GCGGTTCGAACTTTACTTGTACAGCT. After the appropriate 
fragments were gel purified and recovered, the EGFP fragment was 
cloned by ligation into the pT2/SVNeo, giving rise to pT2/EGFP 
constructs. pT2/EGFP and pSB11 plasmid were purified using the 
EndoFree Plasmid Max Kit (Qiagen, CA, USA). Rhodamine-labeling for 
pDNA was performed using a ITTM-Rhodamine labeling kit (Mirus, 
Madison, WI, USA) according to the manufacturer’s protocol.  
2.2.2 Phage selection  
The phage display screening procedure followed the previous 
protocol with a slight modification.110 We used a major coat displayed 
phage library, namely landscape phage library, to perform the biopanning. 
This library contains billions of fd-tet phage clones and in each phage 
clone the foreign peptide is displayed on the N-terminal end of each copy 
of major coat protein of fd-tet phage. Briefly, the landscape phage library 
was first depleted with culture flask at 37°C for 1 h to remove the phages 
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that specifically bound to the culture flask. The depleted phage library 
was incubated with target rMSCs at room temperature for 1 h. The 
rMSCs were washed 10 times with bovine serum albumin (BSA)/Tween 
washing buffer to remove the unbound phages. The cell bound phages 
were eluted with low pH elution buffer (0.1N HCl, 1 mg/mL BSA and 
pH adjusted to 2.2 with glycine) for 10 min. The eluate was neutralized 
by 1 M Tris-HCl (pH = 9.1) immediately. The first-round eluate was 
concentrated by using a Centricon 100 kDa Ultrafilter (Amicon, USA). 
The concentrated eluate was transfected to the starved cells and incubated 
for 15 min at room temperature. The phage-infected cells were added to 
NZY medium with tetracycline (0.2 μ g/mL) and incubated for 45 min at 
37°C with shaking. The tetracycline concentration was increased to 20 μ 
g/mL, and the shaking of the flask was continued for 24 h at 37°C. The 
rMSC-internalized phage clones were recovered using the cell lysis 
buffer (2% sodium deoxycholate, 10 mM Tris-HCl, 2 mM EDTA, pH 
8.0). The cells were centrifuged at 130 g for 10 min. The supernatant was 
removed and the cell lysis buffer was added to the pellet. The phages 
were used for amplification and further selection as stated above. The 
purified phage after each round was used as an input library for the next 
round of selection, which proceeded similarly to the first round as 
described above. After the third round of the selection, the eluted phages 
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were titrated and 40 random colonies were picked up for sequencing in 
order to determine the sequence of rMSC-binding peptides.  
2.2.3 Binding Assessment by Phage Capture ELISA 
 The binding ability and specificity of the selected phages to rMSCs 
were measured by enzyme linked immunosorbent assay (ELISA). 
Confluent cells in 24-well plate (Corning Inc., MA, USA) were fixed by 
4% paraformaldehyde (Sigma-Aldrich Co. LLC, USA) for 15 min, 
blocked with 0.1% BSA for 1 h at room temperature, and washed three 
times with PBS. Subsequently, 2 × 109 cfu purified phages in blocking 
buffer were added and incubated for 1 h at room temperature. The plate 
was subsequently washed three times with PBS containing 0.5% Tween 
20, and washed another three times with PBS. This was followed by 
incubation with anti-fd bacteriophage IgG conjugated with alkaline 
phosphatase (Abcam, MA, USA) for 1 h at room temperature. After a 
final washing step, alkaline phosphatase substrate, p-nitrophenyl 
phosphate, was added to the wells and the absorbance was measured at 
405 nm using a plate reader (Gen5, BioTek Instruments, Inc. USA). 
2.2.4 Peptide-Affinity Assay 
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 The peptide-affinity assay was performed according to the method 
mentioned previously with minor modifications.111,112 The cells were 
cultured until 70–90% confluence, and then incubated with 1 and 10 μM 
FITC-labeled targeting peptide for 4 h at 37°C to allow cell binding. The 
cells were fixed with 4% paraformaldehyde for 30 min at 4°C. The rat 
fibroblastic cells and rat smooth muscle cells were used as control cells. 
They were incubated with 10 μM FITC-labeled targeting peptide for 4 h 
at 37°C to investigate the specificity of peptide. The nuclei were then 
counterstained with DAPI. The cells were observed under a Nikon 
fluorescence microscope.  
2.2.5  Competitive Binding Using Synthetic Peptide 
For specific competitive blocking of peptide, rMSCs (Invitrogen, 
USA) were cultured with targeting peptide or control peptide 
(GCVKYMVM) without FITC at a concentration of 10 μM for 2 h. After 
incubation, 10 μM of FITC-labeled targeting peptide was added and 
incubated for another 4 h. Then the cells were then examined by 
fluorescence microscopy. 
2.2.6 The Preparation and Physico-Chemical Properties of Liposome 
Protamine/DNA Lipoplexes (LPD) 
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 LPD was prepared according to the method reported previously 
with some modifications.113-115 First, the liposomes consisting of DOTAP, 
DOPE and cholesterol (1:1:1 molar ratio) (Avanti Polar Lipids, Inc. USA) 
were prepared by thin film hydration. Second, protamine (0.5 mg/mL) 
(Sigma-Aldrich Co. LLC, USA), various peptides (0.5 mg/mL), and the 
Sleeping Beauty system (pDNA, a mixture of transposon and transposase 
gene at a mass ratio of 2:1) were mixed at various weight ratios. The 
resultant protamine/pDNA complex was allowed to stand at room 
temperature for 20 min. The above liposome was then added into the 
protamine/pDNA complex followed by vortexing. The resultant mixture 
was kept at room temperature for another 20 min to form LPD. 
Protamine/pDNA particles were prepared at different weight ratios, 
and LPD was prepared with various liposome and peptide concentrations. 
The samples were electrophoresed on a 0.8% (w/v) agarose gel in TAE 
buffer at 90 V for 40 min, and analyzed on a UV illuminator to show the 
location of the DNA. 
The size and zeta-potential values of protamine/pDNA particles and 
LPD were determined by dynamic light scattering (DLS) (Zeta Potential 
Analyzer, Brook haven Instruments Corporation, Holtsville, NY). The 
final concentration of pDNA was 20 μg/mL in HEPES buffer for assay. 
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The morphology of LPD was observed using TEM (Carl Zeiss, 
Germany). One drop of LPD was placed on a copper grid and stained 
with 2% uranyl acetate for 3 min. The grid was allowed to dry further for 
20 min and then examined with the electron microscope. 
2.2.7  Gene Transfection  
For the transfection experiments, rMSCs were seeded in the 24-well 
plate at a density of 1 × 105 cells/well and incubated overnight. The 
pDNA was made of a mixture of transposon pT2/EGFP and transposase 
pSB11 with a mass ratio of 2:1 as described in an earlier report116. The 
LPD with various peptides in low glucose DMEM was added, and 
Lipofectamine2000 (Invitrogen, USA) was used as a control. The cells 
were incubated for 4 h at 37°C. The transfection medium was then 
replaced with a fresh culture medium and the cells were further incubated 
for up to 72 h. Inverted fluorescent microscopy was also used to observe 
the GFP expression. The transfected cells was digested by trypsin and 
fixed in a 4% paraformaldehyde for 30 min at 4°C to prepare single-cell 
suspensions. The percentage of cells positive for GFP was determined by 
flow cytometry (Becton-Dickinson Biosciences, Franklin Lakes, NJ, 
USA) by setting a gate according to the control and 1×104 cells were 
evaluated in each experiment. 
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2.2.8 Confocal Microscopy  
LPD was prepared by carboxyfluorescein-labeled DOPE (Avanti 
Polar Lipids, Inc. USA), and the pDNA was labeled with rhodamine as 
mentioned above. The rMSCs were grown on glass cover slips in 12-well 
plates and incubated at 37°C for a day. The cells were then transfected by 
labeled LPD and pDNA complexes. The cells were then incubated for 4 h 
at 37°C. The transfection medium was then replaced with a fresh medium. 
After 5 h, the cells were fixed with 4% paraformaldehyde for 30 min. To 
stain the cell nuclei, the cells were incubated with DAPI for 30 min at 
4°C, and then the cover slips were mounted on glass slides. The 
fluorescence was examined with a confocal laser scanning microscope 
(Leica TCS NT, Germany). 
2.2.9 Cytotoxicity Assay  
Cytotoxicity of LPD was assayed using MTT reagent. Briefly, 
rMSCs were seeded at 1×104 cells per well in 96-well plates. One day 
later, the cells were transfected by LPD with various peptides at different 
liposome concentration. The Lipofectamine 2000 was used as the control. 
The cells were incubated for another 12 h at 37°C. The medium was 
replaced with 80 μL of fresh medium without serum and 20 μL of MTT 
(5 mg/mL) (Sigma-Aldrich Co. LLC, USA) solution, and incubated for 
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an additional 4 h. Subsequently, the medium was removed and 100 μL of 
dimethyl sulfoxide (DMSO) was added. The absorbance at 570 nm was 
measured by using a microplate reader. 
2.2.10 Osteogenesis Assay 
 1 × 105 transfected or untransfected MSCs/well were seeded in a 
24-well plate in triplicate. After 24 h, medium was removed and 500 μL 
of HyClone osteogenic differentiation medium (Thermo Fisher Scientific 
Inc., USA) was added. Medium was changed every 3 days. Cultures were 
harvested at day 14. To analyze osteopontin expression, cells were fixed 
with 4% paraformaldehyde. Cells were saturated with 5% BSA for 30 
min. 300 μL of anti-osteopontin antibody (ab 8448-200, Abcam, MA, 
USA), which was diluted 1:300 in phosphate buffered saline (PBS) 
containing 5% BSA, was added and incubated overnight at 4°C. The cells 
were then washed with PBS/5% BSA and incubated with a secondary, 
tetramethylrhodamine goat anti-rabbit IgG (H+C) (Molecular probes, 
Invitrogen, USA) for 60 min at room temperature. The nuclei were 
stained by DAPI. The cells were observed with a fluorescence 
microscope. 
2.2.11  Statistics analysis 
38 
 
 For statistical analysis, one-way analysis of variance (ANOVA) 
was carried out by SPSS 11 software, and a p values < 0.05 were 
considered statistically significant. 
2.3  Results 
2.3.1  Identification of rMSC-Homing Phage Clones 
rMSC-homing phage clones were isolated from a major coat 
displayed phage library after three rounds of panning. The major coat 
displayed phage library, also termed landscape phage library, is made of 
billions of fd-tet phage clones with each phage clone fully displaying a 
unique foreign peptide on the major coat. Namely, for each phage clone, 
the foreign peptide is fused to each of the ≈3900 copies of major coat 
protein of fd-tet phage. Phages that were bound to rMSCs in the initial 
selection procedure were amplified separately by infecting bacteria and 
used as an input for the next round of affinity selection. After the three 
rounds of affinity selection, 51 clones were randomly picked and 
sequenced. The cell-binding peptides and their frequencies are shown in 
Table 2.1. No cell internalized phages were detected after cell lysate 
amplification and phage titering. The cell-binding phage clones with a 
sequence of VTAMEPGQ demonstrated the highest affinity to rMSCs. 
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Phage capture ELISA also indicated that the selected cell-binding phage 
with sequence VTAMEPGQ has high affinity against rMSCs (Figure 2.1). 
 
     Motif  ID        Motif Sequence     Frequency 
#1 VTAMEPGQ 28 
#2 AFNPEPGQ 11 
#3 VTALEPGQ 7 
#4 DTPPGWDQ 5 
Table 2.1  Peptide sequences displayed by selected rMSC-binding phage 




Figure 2.1  Binding of control wild type phage and affinity selected 
phages to rMSCs evaluated by ELISA.  The x axis indicates the 
absorbance of ELISA signal and the y axis shows the affinity selected 
peptide sequences displayed on the major coat of phage. 
2.3.2  rMSC-affinity and specificity of the identified peptide.  
The identified peptide (VTAMEPGQ) was designated as peptide 1 
(Table 2.1). A randomly scrambled peptide (GCVKYMVM, peptide 4) 
was used as the negative control. The rMSCs were incubated with FITC 
labeled peptide 1 or 4, and observed using a fluorescence microscope. 
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When incubated with 10 uM FITC-peptide 1, strong fluorescent signals 
were observed in rMSCs (Figure 2.2b), whereas a weak FITC signal was 
detected of 1 μM FITC-peptide 1 (Figure 2.2a). When incubated with 
1μM and 10 μM FITC-labeled scrambled peptide 4, no specific 
fluorescence signal was observed from rMSCs at both concentrations 
(Fig. 2.2c and 2.2d). This result suggests that peptide 1 can bind with 
rMSCs in a concentration dependent way. But scrambled peptide 4 is not 
able to bind to rMSCs specifically. 
 
Figure 2.2  Cellular affinity of peptide 1 with rMSCs. Strong fluorescence 
signals were visualized, indicating that plenty of 10 μM FITC-labeled 
42 
 
peptide 1 located in rMSCs (b). Weak fluorescence was detected from 1 
μM FITC-labeled peptide 1 in rMSCs (a). No specific fluorescence signal 
was observed from both 1 and 10 μM FITC-labeled peptide 4 (c, d). The 
nucleus was stained with DAPI. Scale bar: 100 μm. 
2.3.3  Competitive Binding Using Synthetic Peptide.  
In order to verify whether internalization of peptide 1 takes place 
through a VTAMEPGQ recognition motif, competitive assay was 
performed by pre-binding of peptide 1 or 4 without FITC to rMSCs. 
Peptide 1 or 4 was incubated with the cells prior to the incubation of 
FITC-labeled peptide 1. Figure 2.3 shows that pre-incubation with un-
labled peptide 1 reduced the binding of FITC-labeled peptide 1 to the 
rMSCs, but the pre-incubation with peptide 4 didn’t affect the binding of 
FITC-labeled peptide 1 with rMSCs. This fact confirms that FITC-
labeled peptide 1 is competitively inhibited in the presence of peptide 1, 






 Figure 2.3   Blocking binding to rMSCs in the presence of peptide 1 or 4. 
rMSCs were pre-incubated with 10 μM peptide 1 (a) or 4 (b) without 
FITC followed by incubation with 10 μM FITC-labeled peptide 1. 
Fluorescence microscopy confirmed that rMSCs preincubated with 
peptide 4 displayed much stronger fluorescence signals (b) than those 
preincubated with peptide 1 (a). The nucleus was stained with DAPI. 
Scale bar: 100 μm. 
2.2.4  Preparation and Physico-Chemical Properties of Liposome 
Protamine/DNA Lipoplexes (LPD) 
To construct the LPD, we used a two-step packaging technology 
employing a multilayering method. First, the DNA was packaged into a 
condensed core via electrostatic interactions with protamine. The 
targeting peptide with slightly positive potential was also added and 
interacted with the plasmid to form a negatively charged particle. Second, 
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positively-charged DOTAP/DOPE/Chol liposome was added to form a 
complex with negative protamine/DNA particle, leading to the formation 
of LPD (Figure 2.4). 
The formation of LPD was verified via gel electrophoresis and zeta 
potential measurement. According to the results of gel electrophoresis, 
DNA migration started to be retarded when the weight ratio of protamine 
to pDNA reached 1.5:1 for the protamine to condense the DNA (Figure 
2.5). Thus, the protamine/pDNA particle was prepared at a weight ratio 
of 1:1 to ensure that its zeta potential was negative to favor its integration 
with the DOTAP/DOPE liposome. 
The results of dynamic light scattering (DLS) showed that the zeta 
potential of the protamine/pDNA complex was negative and 245.7 nm in 
size at the weight ratio of 1:1 (Table 2.2), which was consistent with the 
result of gel electrophoresis. At a weight ratio of 1.5:1, the particle of 
protamine/pDNA became positive in potential and 118.5 nm in size, 






Figure 2.4 Schematic illustration of targeting LPD modified with rMSC-
homing peptide and NLS peptide. 
 




Protamine:pDNA = 1:1 245.7 ± 6.47 –27.55 ± 3.33 








LPD (10 mM liposome) 245.1 ± 5.65 20.74 ± 1.89 
Table 2.2  Particle size and zeta potential of protamine/pDNA particles 
and LPD. The pDNA concentration was 20 μg/mL. The concentration of 
liposome is denoted by the concentration of DOTAP in LPD.  
 
 
Figure 2.5 Agarose gel electrophoresis retardation assay of 
protamine/pDNA polyplexes at various weight ratios. The mixtures were 
incubated at room temperature for 20 min, subject to electrophoresis on a 
0.8% (W/V) agarose gel and stained with ethidium bromide. 
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The LPD was then prepared with various concentrations of 
liposome. The gel electrophoresis and DLS were both performed to 
verify the formation of the LPD. With the increasing concentration of 
liposome, DNA migration was retarded gradually (Figure 2.6). The 
protamine/pDNA particles could be complexed completely with 
DOTAP/DOPE liposome at a concentration of 10 mM DOTAP. The 
results of DLS were consistent with those of the gel electrophoresis. After 
being incorporated with the DOTAP/DOPE liposome, LPD had a zeta 
potential of positive 20.74 mV, and was 245.1 nm in size (Table 2.2). The 





Figure 2.6  Gel assay of LPD at various liposome concentrations 
(protamine/pDNA = 1:1), using pDNA as a control. The protamine and 
pDNA were mixed at weight ratios of 1:1 and the complex was incubated 
for 20 min at room temperature. Then, the DOTAP/DOPE/Chol liposome 
was added into the complex followed by mixing and standing at room 
temperature for 20 min and electrophoresis on 0.8% (W/V) agarose gel. In 
this study, liposomes were prepared from synthetic phospholipids. Their 
main components include DOTAP and DOPE. The molecular weight of 
DOTAP and DOPE is 758.19 Da and 744.03 Da, respectively. The 
molecular ratio between them is 1:1. The concentration of liposomes was 




Figure 2.7  Morphology of LPD observed by transmission electron 
microscope. The particles were negatively stained by 2% uranyl acetate 
for 3 min. 
2.3.5  Transfection Efficiency 
To investigate the peptide-enabled targeted delivery efficiency, we 
performed the transfection efficiency study using LPD with the synthetic 
targeting peptide 1. Lipofectamine 2000 served as a control (Figure 2.8A). 
The result showed that the transfection efficiency of LPD with peptide 1 
was 3.24- and 1.41-fold higher than Lipofectamine2000 and LPD without 
peptide, respectively, showing enhanced targeted gene delivery to rMSCs. 
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This indicates that peptide 1 enhanced transgenic expression by means of 
targeting to rMSCs. This demonstrated the great potential of peptide 1 as 
a ligand in rMSCs targeting. 
To further enhance the nuclear translocation efficiency of SB 
transposon system, three-fold reiterated NLS motif 
(DPKKKRKVDPKKKRKVDPKKKRKV, peptide 2) of SV40 T large 
antigen was employed to promote the nuclear translocation and gene 
expression of LPD.117 To investigate the effect of fused peptide, an LPD 
with a fusion peptide 
(DPKKKRKVDPKKKRKVDPKKKRKVVTAMEPGQ, peptide 3) from 
peptides 1 and 2 was compared to the LPD containing unfused peptides 1 
and 2. The results showed that LPD with fusion peptide 3 did not 
demonstrate a better gene expression than sole peptide 1 or 2. This means 
that after fusion, peptides 1 and 2 did not produce an improved effect. 
However, LPD with both unfused peptides 1 and 2 integrated could 
obtain the highest gene expression among all the peptide combinations. 
This indicates that a synergetic effect could be realized by encapsulating 
both peptides 1 and 2 in LPD. The fluorescence microscopy results also 




Figure 2.8  Transfection efficiency of LPD in rMSCs. Lipofectamine 
2000 was used as the control. A) EGFP expression after transfection by 
LPD with various peptides was examined by flow cytometry. LPD with 
both unfused peptides 1 and 2 integrated could obtain the highest gene 
expression among all peptides tested. Fusion peptide 3 (fused from 
peptides 1 and 2) did not display a better gene expression. The percentage 
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of EGFP positive cells is shown as the mean ± standard deviation of 
triplicate measurements. (*) indicates a statistically significant difference 
(p < 0.05). B) Comparison of transfection expression of EGFP mediated 
by Lipofectamine2000 (a), LPD (b), and LPD with peptide 1 (c), peptide 2 
(d), peptide 3 (e), peptide 1 + 2 (f) in rMSCs using the transposon 
containing EGFP reporter gene. Image 1 in (a–f) shows GFP expression 
and image 2 is the corresponding bright-field light image. Scale bar: 100 
μm. 
The LPD with various combinations among the peptides 1, 2, and 3 
was then investigated for a higher transgenic efficiency (Figure 2.9A). 
The result showed that the combination of peptides 1 and 2 was still 
better than the other two combinations. The effects of varying 
peptide/plasmid weight ratio on transfection efficiencies into rMSCs were 
determined to ascertain an optimal dosage. Using a 3:1 peptide to plasmid 
ratio resulted in the best gene expression among all examined 
peptide/plasmid ratios (Figure 2.9B). A decreased transfection efficiency 
of LPD was observed at ratios higher or lower than the 3:1 of 
peptide/plasmid ratio. It was therefore concluded that using a 3:1 
peptide/plasmid ratio was optimal for further use. 
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To verify the effect of peptides 1 and 2, the random peptide 
(GCVKYMVM, peptide 4) was utilized as a substitution and combined 
with either peptide 1 or 2 in LPD for gene transfection. The results 
showed that compared to peptides 1 and 2, the random peptide did not 
increase any transfection efficiency of LPD in rMSCs (Figure 2.9C). 
After being combined with peptide 1 or 2, peptide 4 still did not result in 
an improved transfection efficiency. It further confirmed that there was a 
synergetic effect between peptides 1 and 2, i.e., between rMSC-homing 
and NLS peptide. These two peptides should be co-existing (but without 
forming fusion peptide) to maximize the transfection efficiency of LPD. 
A time course of gene expression was then performed for SB 
transposon system (made of pT2/EGFP and pSB11 at a mass ratio of 2:1) 
and pEGFP-N1 genes with expression levels measured up to 168 h 
(Figure 2.9D). After 96 h, the transgenic expression level of SB 
transposon system in rMSCs reached its maximum, which was referred to 
as 100%. After 24 h, relatively low SB transposon system and pEGFP-N1 
transfection rates of only about 50% of maximum of transposon 
transfection were observed. Transfection of pEGFP-N1 reached its 
maximum at 72 h, which was only about 70% of the transposon system's 
maximum, and with no further significant increase seen at 96 h. The 
transfection rates of pEGFP-N1 then decreased significantly to 
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approximately 50% after 144 and 168 h. The transposon system did not 
show obvious decreases in transfection levels at 120, 144, and 168 h, 
which are all maintained at about 90% of the maximum. 
 
Figure 2.9   Comparison of gene transfection efficiencies. A) The EGFP 
expression level of LPD with different combinations of the peptides 1, 2, 
and 3. The combination of peptides 1 and 2 was superior to the other two 
combinations. B) The transfection efficiency of LPD with the various 
peptide/plasmid weight ratios. LPD with peptide/plasmid ratio of 3:1 was 
optimal for gene expression. C) A control peptide (peptide 4) was utilized 
to verify the synergetic effect between peptides 1 and 2. Peptide 4 did not 
promote transfection of LPD neither solely nor combining with peptide 1 
or 2. D) Percentage of EGFP positive cells in rMSCs after varying the 
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duration of transgene expression. The highest transfection levels were 
observed at 96 h with the SB transposon system gene, which was set as 
100%. SB transposon system maintained about 90% of its maximum after 
168 h. However, pEGFP-N1 showed obvious decreases in transfection 
levels at that time. Each assay was shown as means ± standard deviation 
(n = 3). (*) Indicates a statistically significant difference (p < 0.05). 
2.3.6  Confocal Microscopy 
For investigating the intracellular localization of LPD with or 
without NLS peptide, carboxyfluorescein labeled DOPE was used to 
prepare liposome. The pDNA was labeled with rhodamine. The cells 
were scanned with a confocal fluorescence microscope. After the cells 
were transfected with LPD containing the NLS peptide, rhodamine-
labeled pDNA colocalized with the nuclei as indicated by white arrows in 
Figure 2.10A(d). However, LPD without the NLS peptide rarely 
translocated pDNA into the nuclei (Figure 2.10B). This result indicates 
that the NLS peptide guides the nuclear translocation of pDNA efficiently. 
This efficient translocation into the nucleus may be responsible for the 




Figure 2.10  Subcellular distribution of LPD with and without NLS 
peptide 2 (A and B, respectively) was visualized by confocal microscopy 
in rMSCs. a: DAPI labeled nuclei (blue); b: rhodamine labeled pDNA 
(red); c: carboxyfluorescein labeled liposome (green); d: merged images 
of a, b, and c. Guided with NLS peptide, LPD and rhodamine-labeled 
pDNA could colocalize in the nuclei. However, without NLS peptide, 
LPD and pDNA rarely appeared into the nuclei. Scale bar: 31.75 μm. 
White arrows in A(d) are used to indicate that rhodamine-labeled pDNA 
colocalized with the nuclei. 
2.3.7  Cytotoxicity 
In vitro cytotoxicity of various concentrations of LPD and 
Lipofectamine 2000 was investigated with rMSCs after 12 h incubation at 
37°C by MTT assay (Figure 2.11). At Lipofectamine 2000 concentrations 
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over 40 mM, cell viability was lower than 80%, indicating that it has 
obvious toxicity at these higher concentrations. Cell viability was slightly 
reduced at higher concentrations of LPD, but still higher than 80%. This 
fact demonstrates that LPDs with peptides show low cytotoxicity with 
good biocompatibility. Furthermore, there was no significant difference 
in the toxicity of different formulation at all given concentrations (p < 
0.05). 
 
Figure 2.11  MTT assay for evaluating cytotoxicity of LPD with various 
peptides at different liposome concentrations. Lipofectamine 2000 was 
used as a control. The cell viability of samples with LPD with peptides at 
all liposome concentrations was higher than 80%. Lipofectamine 2000 had 
obvious toxicity at concentrations over 40 mM. The concentration of 
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liposome is denoted by the concentration of DOTAP in LPD. The data 
points represent the mean ± standard deviation of three experiments. 
2.3.8  Cell Differentiation test 
Osteogenesis of rMSCs after transfected by LPD was determined by 
the production of LPD after 14 days in an osteogenic medium. 
Osteopontin is a bone marker protein and its expression by osteoblasts 
differentiated from rMSCs was used as a marker to verify the osteoblastic 
differentiation of rMSCs. Similar to untransfected rMSC (Figure 2.12B) 
but unlike the undifferentiated control (Figure 2.12C), LPD-transfected 
rMSCs (Figure 2.12A) retained the ability of rMSCs to differentiate 





Figure 2.12  Osteogenic differentiation assays of rMSCs. A) 
Differentiation of LPD-transfected rMSCs in an osteogenic medium. B) 
Differentiation of untransfected rMSCs in an osteogenic medium. C) The 
undifferentiated rMSC was tested as a control. Image 1 in (A–C) shows 
cell nuclei using DAPI stain (blue); image 2 is GFP expression (green); 
image 3 shows immunofluorescence staining of osteopontin-positive cells 
(red); image 4 is merged from images 1, 2, and 3. No differences in 
osteogenic differentiation were observed between transfected and 
untransfected rMSCs, but the differentiation of both transfected and 
untransfected rMSCs was different from the undifferentiated control. 
Scale bar: 100 μm. 
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2.4  Discussion 
MSCs are multipotent cells, which hold a tremendous promise for 
the construction and regeneration of tissues. However, MSCs by 
themselves have exhibited limited efficacy in terms of tissue regeneration 
and differentiation to the desired cell types. Therefore, genetic 
engineering has been proposed as a method to enhance the efficacy of 
MSC-based therapies. Genetic modification of stem cells by transposons 
to obtain sustained gene expression may further enhance their therapeutic 
efficacy. 
Sleeping Beauty (SB) is a Tc1/mariner-like transposon system, 
artificially reconstructed by site-directed mutagenesis from an inactive 
salmonid transposable element.118 After expression in a cell, SB 
transposases bind to the SB inverted/direct repeat elements (IRs/DRs) in 
a substrate-specific manner and induce transposition by a ‘‘cut-and-paste’’ 
mechanism, inserting a transposon into a new genomic location 
containing TA dinucleotides.118,119 Transposon integration occurs with 
little preference for the transcriptional status or genetic identity of the 
sequence into which the SB transposon integrates.119-122 Since its 
introduction, the SB transposon system has been tested in numerous 
model organisms to correct several genetic deficiencies.123 
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Although proof-of-principle studies using non-viral gene delivery 
have established the potential of SB-mediated insertion into the host 
genome for long-term gene correction,124 the delivery is nonselective. 
Thus, an efficient cell type-specific targeting system is desirable to fully 
investigate the potential of SB and other vertebrate transposon vector 
systems for gene therapy. 
We constructed LPD for a targeted transposon delivery. This 
structure is advantageous in terms of integrating various functional 
devices for controlling intracellular trafficking into one nanoparticle. The 
LPD was a nanoparticle formed solely by charge-charge interactions, 
specifically, between preformed cationic liposomes, and an anionic 
complex of protamine, targeting peptides and anionic nucleic acids. First, 
the plasmid was condensed by protamine into a negatively charged 
compact core. The complex should only contain the required amount of 
protamine that can provide sufficient concentration but keep the complex 
negatively charged. Then, the complex interacted with the cationic 
liposome to form the LPD. Again, the LPD should only contain a slight 




According to the result of zeta-potential measurement, 
protamine/pDNA particle at a 1:1 weight ratio had a negative potential. 
After being incorporated with DOTAP/DOPE/Chol liposome, the zeta 
potential of particles was shifted to positive, which confirmed the 
formation of LPD. The gel electrophoresis, which was consistent with 
zeta potential measurement, also demonstrated the shift of zeta-potential. 
The highly positively charged surface of LPD (zeta potential ≈20 mV) 
would favor the strong charge-charge interaction with the cells, which 
could increase the association with the cells during gene transfection. The 
diameter of LPD was approximately 200 nm, which would facilitate its 
endocytosis by cells.125 
Three rounds of consecutive phage display panning were conducted 
to select peptide ligands which can target rMSCs specifically. After 
panning, four peptide sequences were identified from randomly selected 
individual recombinant phages. Based on the recovery efficiency and 
phage capture ELISA results, we categorized the peptide VTAMEPGQ as 
the best binder to rMSCs under stringent conditions. rMSCs-affinity 
assay showed that as the concentration of peptide increases, more FITC-
labeled peptide 1 was located in rMSCs, but neither high nor low 
concentrations of control peptide 4 induced localization into rMSCs. 
Furthermore, the affinity between dye-labeled peptide 1 and rMSCs was 
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competitively inhibited in the presence of peptide 1. However, the 
affinity of dye-labeled peptide 1 for rMSCs was not affected by control 
peptide 4. After the FITC-labeled peptide 1 was interacted with two 
different control cells (rat fibroblastic cells and rat smooth muscle cells) 
separately, we found that peptide 1 did not bind any of the two control 
cells. These facts confirm that peptide 1 has high targeting specificity and 
affinity against rMSCs. Thus, we selected peptide 1 as rMSCs-homing 
peptide candidate for the rest of our study. 
The transfection experiment showed that transgenic activity of LPD 
could be promoted by either peptide 1 or 2. This indicates that peptide 1 
could target to rMSCs and enhance the endocytosis of LPD mediated by 
receptor. The peptide 2 could direct plasmid into the nuclei to improve 
the interaction between the exogenous gene and the host genome. Peptide 
3 is fused from peptides 1 and 2 and did not display better action than the 
original sequences. It is assumed that the function of the two peptides 
might be degraded by steric hindrance after being fused together, thus 
resulting in their inactivity. 
After being combined with both unfused peptides 1 and 2, LPD 
mediated a higher gene expression. It was suggested that LPD could 
firstly home to and enter the rMSCs by means of peptide 1, and then, be 
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guided by peptide 2 to translocate into the nuclei and achieve efficient 
gene delivery. The two peptides executed their actions at the right space 
and time, resulting in a synergetic effect. Other combinations of the three 
peptides did not show the optimal transfection action as shown by 
peptides 1 and 2.  
To verify the synergetic effect of peptides 1 and 2, one of them was 
replaced with the control peptide 4 for the combination. The control 
peptide 4 did not possess any function to improve transfection. Moreover, 
the peptide 4 also could not execute a synergetic effect with either 
peptide 1 or 2. This demonstrates that peptides 1 and 2 could assist each 
other exclusively to achieve optimal transgenic action. 
It was shown that the optimal transgenic action can be completed at 
a 3:1 peptide plasmid ratio. This suggests that a lower quantity of peptide 
could not execute its function to target the cell and nucleus efficiently. 
Additionally, when the quantity of the peptide is too high, its receptor 
might be blocked, resulting in a depressed targeting transposition. This 
phenomenon is the so-called “excess inhibition” of receptors. 
Confirmation of the delivery of transposon into the nuclei by LPD 
was supported by confocal microscopy. This result showed that LPD with 
peptides 1 and 2 can accumulate into nucleus efficiently but when LPD 
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was modified with only peptide 1, the plasmid failed to translocate into 
the nucleus. This fact suggests that the NLS peptide contributes to the 
efficient nuclear localization of the complexes. The nuclear localization is 
very important for transposon transfection. Since transposons do not have 
the transducing abilities of viral vectors, it is necessary to devise a 
method to deliver this plasmid-based system into cells efficiently. The 
transposition rate is critically dependent on the efficiency of uptake of the 
plasmids into the cell nuclei. After being guided into the nucleus by NLS, 
transposon had a high opportunity to integrate into host genome, causing 
substantially increased transfection efficiency. 
One of the major barriers of non-viral gene delivery is the transient 
nature of gene expression. Therefore, stable genomic integration is a 
particularly attractive feature to enable stable transduction of dividing 
target cells, especially for stem cells, and their differentiated progeny. We 
performed a time course of gene expression levels using transposon. The 
levels of gene expression were examined up to 168 h both from pEGFP-
N1 and transposon in rMSCs. For the pEGFP-N1, a gradually reduced 
expression level was observed after 96 h. However, the transposon 
maintained 90% of its maximum transfection even after 168 h, which 
appeared to increase the duration of gene expression. The transgenic 
activity of transposon was also superior to the pEGFP-N1 as 1.43 times. 
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This suggested that the expression of the SB transposase gene on 
transposition rates will trigger the activity of SB transposon to increase 
insertion rates of transgenes into cellular chromosomes.126 Thus, the 
transposon system could yield unprecedented stable and durative gene 
transfer efficiencies that compare favorably to the stable transduction 
efficiencies of integrating viral vectors.127,128 This system is expected to 
facilitate widespread applications in functional genomics and gene 
therapy. 
It was shown that LPD was relatively safer than Lipofectamine 
2000. No notable toxicity was observed for LPD among any of the given 
concentrations. This might result from the biocompatibility of liposomes 
and peptides. LPD was found to have no negative effect on the 
differentiation potential of rMSCs. Cells transfected with the LPD were 
able to differentiate into the osteogenic lineage as were the un-transfected 
cells. Thus, LPD with various peptides was regarded as a safe gene 
delivery system. Furthermore, it can be utilized over a larger range of 
dosages. Accordingly, LPD is a promising gene carrier without any 
significant adverse effects on the rMSCs. 
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2.5  Conclusions 
In conclusion, we identified an rMSC-targeting peptide by phage 
display. A liposome protamine/DNA lipoplex (LPD) was constructed by 
combining the targeting peptide and a nuclear localization signal (NLS) 
peptide with a Sleeping Beauty transposon delivery system. Our results 
show that the selected peptide can improve the transfection efficiency due 
to its rMSC-targeting property. The rMSC transfections mediated by LPD 
with the targeting peptide and NLS peptide were much more efficient 
than those mediated by the randomly chosen control peptide. We also 
found that the targeting peptide and NLS peptide could have a synergetic 
effect to promote efficient and lasting transfection expression of 
transposon. Furthermore, LPD neither showed apparent cytotoxicity nor 
disturbed the osteogenic differentiation of rMSCs. Therefore, a liposome-
based nanoparticle combined with NLS and rMSC-homing peptide was 
developed for targeted delivery of the transposon system to rMSCs, 
yielding stable and durative gene transfer efficiency, making it a 




Chapter 3 Reiterated targeting peptides on the nanoparticle 
surface significantly promote targeted vascular endothelial 
growth factor (VEGF) gene delivery to stem cells 
3.1  Introduction 
 Stem cell-based gene therapy is a promising approach to the 
treatment of many diseases such as myocardial ischemia129,130, bone 
defects131,132 and cancer133,134. In this approach, a foreign gene, such as 
the one encoding vascular endothelial growth factor (VEGF), is carried 
by stem cells such as mesenchymal stem cells (MSCs) and the transfected 
stem cells are implanted into the diseased sites (e.g., ischemic heart), 
followed by the expression of the gene into a functional protein (such as 
the VEGF that can induce blood vessel formation to repair the ischemic 
heart). MSCs are considered a good cell carrier in stem cell-based gene 
therapy because they also have the potential to differentiate into bone, 
muscle, cartilage and other connective tissues. This multipluripotency 
makes MSCs attractive candidate for gene therapy135. VEGF is essential 
for vasculogenesis and angiogenesis to regenerate new blood vessels136. 
Hence, it is a good therapeutic protein in treating diseases where new 
blood vessel formation is the key, such as the  healing processes of 
damaged bones 137. Study showed that MSCs expressing VEGF hold 
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potential for treating various disease138-140.  Study also showed that 
viruses can carry gene in gene therapy with a high efficiency3,141-144. 
However, they are not ideal carriers because they can potentially induce 
mutagenesis and immune responses. To overcome such challenges, non-
viral vectors such as nanoparticles (NPs)145-148, cationic lipids149-151 and 
polymers68,152,153 are proposed for gene delivery to MSCs. However, due 
to the lack of efficient internalization, nuclear translocation and 
integration of foreign genes into host genome, the non-viral vectors 
generally have low transfection efficiency (typically lower than 20%), 
particularly when they are used to deliver the gene into the hard-to-
transfect stem cells. Thus there is a pressing need in the development of a 
biocompatible and efficient non-viral vector for gene delivery to MSCs. 
      Previously we showed that a peptide (VTAMEPGQ, termed 
VT-peptide) that can target bone marrow-derived rat MSCs (rMSCs) 
could be selected from a random peptide library by using phage display 
technique154. We also showed that when the peptide was mechanically 
mixed with lipids to form liposomes, only leaving a few molecules on the 
surface, the EGFP gene transfection efficiency could be improved from 
~8% to ~12%. We then hypothesized that if the peptide was presented on 
the surface of nanoparticles by chemical conjugation with the surface 
molecules, the nanoparticles will have a higher efficiency of recognizing 
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the rMSCs and becoming internalized, leading to improved efficiency of 
delivering gene into rMSCs. Moreover, once gene is delivered into the 
rMSCs, the gene needs to be translocated to the cell nuclei and also 
inserted into the host genome for gene expression. To assist these two 
important steps, we adopt two measures. One is to integrate a reported 
nuclear localization signaling (NLS) peptide (DKKKRKV) with the DNA 
to be delivered155,156. Another is to use a non-traditional special type of 
plasmid, a sleeping beauty (SB) transposon system, which is a mixture 
made of a transposon and a transposase157,158. The transposon carries the 
VEGF target gene and the transposase acts as an enzyme that can “cut” 
the VEGF gene from the transposon and “paste” it into the host genome 
of rMSCs. The “cut-and-paste” mechanism ensures the target gene to be 
expressed in a long-lasting manner instead of the undesired transient 
manner.  In essence, to solve the two daunting challenges facing the use 
of non-viral nanoparticles to transfect MSCs, namely, the low efficiency 
of delivering gene to the cells and transient production of functional 
protein, we allow the rMSC-targeting peptide to be chemically 
conjugated to the surface of lipid-based nanoparticles (LBNs), which 
deliver a VEGF-encoding SB transposon system complexed with a 
cationic NLS peptide to rMSCs. 
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  Specifically, we employed a three-fold reiterated rMSC-targeting 
peptide (VTAMEPGQVTAMEPGQVTAMEPGQC, termed 3VT-
peptide) to study if we can observe enhanced transfection effect. Non-
reiterated VTAMEPGQC (VT-peptide) was used as a control. A cysteine 
at the C-terminal of peptide was introduced to facilitate peptide-lipid 
conjugation. Second, in contrast to the conventional plasmid vectors, the 
SB system provides efficient and long-term gene expression. Third, in 
order to overcome the nuclear membrane barrier, we incorporated the 
NLS peptide to enhance nuclear translocation of DNA. The NLS peptide 
has been proven to promote gene expression to mammalian cells156,159. 
Fourth, the arginine-rich polycationic protamine is used as a condensation 
reagent. Studies showed that protamine was able to condense plasmid 
DNA efficiently to promote gene delivery to several cell types in 
combination with liposome160,161. The fabricated nanoparticles display 
rMSC-targeting motif on the surface and carry an electrostatically 
condensed mixture of NLS peptide, protamine and SB system inside, 
promoting MSC-internalization， nuclear translocation and integration of 
target gene into MSCs genome, all of which collectively resulted in 
enhanced sustained gene expression.  
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3.2 Materials and methods 
3.2.1 Materials 
All the lipids such as 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[maleimide(polyethylene glycol)-2000] (DSPE-PEG2000-MAL), mini 
extruder and polycarbonate membrane filters were purchased from 
Avanti Polar Lipids Inc. Cholesterol, protamine and chloroform were 
purchased from Sigma Aldrich. Fetal bovine serum (FBS), Dulbecco's 
Modified Eagle Medium (DMEM), SYBR Safe and lipofectamine® 2000 
were purchased from Invitrogen. 
3.2.2 Construction of VEGF SB transposon system 
We obtained the pEGFP-VEGF plasmid containing VEGF and 
EGFP gene from Professor H. K. Lin (the Health Science Center, 
University of Oklahoma). The original sleeping beauty transposon 
pT2/SVNeo (the transposon) and pSB11 (the transposase) were a kind 
gift from Dr. Perry B. Hackett (University of Minnesota). The neomycin 
resistance gene in pT2/SVNeo was replaced by VEGF and EGFP gene 
(Figure 3.13). First, DNA fragments containing VEGF and EGFP gene 
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were amplified by PCR from pEGFP-VEGF plasmid (Primer1: 
GCCTGATCAATGAACTTTCTGCTGTCT; Primer2:  
GCCTTCGAATTACTTGTACAGCTCGTC), the underlines denote the 
introduced restriction enzyme sites. Second, both the DNA fragments and 
pT2/SVNeo plasmids were digested by restriction enzyme BclI and BstBI. 
Finally, the digested products were purified and ligated to give rise to the 
recombinant pT2/VEGF plasmid. The purified pT2/VEGF plasmids were 
verified by DNA sequencing (MCLAB).  
3.2.3 Preparation of Liposome 
The liposomes consisting of DOTAP, DOPE and cholesterol (1:1:1 
molar ratio) were prepared by thin film hydration. Briefly, a thin lipid 
film was formed by evaporating the lipid solvent with nitrogen gas in a 
10 ml round bottom flask. Hydration of the lipid films was done with 
vigorous vortexing for 1h, followed by sonication for 5 min. The 
resultant liposomes were repeatedly extruded (9 times) at room 
temperature through polycarbonate membranes filters of decreasing pore 
size of 0.2 and 0.1 mm respectively using a mini extruder.  
3.2.4 Conjugation of targeting peptide with DSPE-PEG2000-MAL 
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VTAMEPGQGGGC peptide (VT-peptide, MW=1106.25) or 
VTAMEPGQVTAMEPGQVTAMEPGQGC (3VT-peptide, 
MW=2620.01) were synthesized by United BioSystems Inc. The 
reduction of cysteine residues in the targeting peptide was first performed. 
Briefly, 5 ml peptide (100 μM, PBS, pH7.5) was first mixed with tris (2-
carboxyethyl) phosphine (TCEP) (2 mM) with a 1:2 ratio of 
peptide/TCEP. The reaction was allowed to proceed at 37 oC for 2 h. A 
10 μl DSPE-PEG2000-MAL (10 mM) stock solution was reacted with 5 
ml (100 μM) of the reduced peptide in PBS buffer (pH 7.5), 
corresponding to 5:1 molar ratio of reduced peptide to maleimide groups. 
The conjugation reaction was carried out for 3 h at room temperature. 
Conjugated peptide-PEG-DSPE was purified by dialysis (500 Da 
membranes). 
3.2.5 Preparation of targeting LBNs 
To obtain targeting liposome, the insertion of the peptide 
conjugated lipid (peptide-PEG-DSPE) into liposomes was performed by 
employing a post-insertion technique. Targeting liposomes were prepared 
with varied peptide-PEG-DSPE:liposome molar ratios at 0.1%, 0.5%, 1%, 
5% and 10%. For this purpose, liposome (20 mM, as denoted by DOTAP 
in liposome) in water solution was incubated with a various amount of 
75 
 
peptide-PEG-DSPE for 1 h with vortexing. The resultant solution was 
kept at 60 ° C for 1 h. As a result, the conjugates became attached to the 
outer lipid layer of the vesicles via hydrophobic DSPE domain. The size 
and zeta-potential values of liposome in water solution were determined 
by dynamic light scattering (DLS) (Zeta Potential Analyzer, Brook haven 
Instruments Corporation, NY). 
3.2.6 Gel retardation of protamine/pDNA polyplexes 
The protamine and pDNA (0.25 g) were mixed at different weight 
ratios and incubated for 20 min. The resultant complexes were confirmed 
using gel electrophoresis (1% agarose gel, 105 V, 40 min, with SYBR 
Safe staining). 
3.2.7 Gel retardation of Liposome Protamine/DNA Lipoplexes 
The protamine and pDNA (0.25 g) were mixed at a weight ratio of 
2:1 and the complex was incubated for 20 min. Then, the 
DOTAP/DOPE/Chol (Mole ratio 1:1:1) liposome was added into the 
complex followed by incubation for 20 min. The resultant complexes 
were confirmed using gel electrophoresis as shown in Figure 3.5 (1% 
agarose gel, 105 V, 30 min, with SYBR Safe staining). 
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3.2.8 Preparation of LBN  
Sleeping Beauty plasmids (transposon and transposase plasmids at 
2:1 mass ratio) and protamine, NLS peptides were mixed at various 
weight ratios to form polyplex. The resultant polyplex was allowed to 
stand at room temperature for 30 min. Then liposome was added into the 
polypex solution followed by vortexing. The resultant mixture was 
incubated for 1 h to give rise to LBN. 
3.2.9 MTT Assay 
The cells were seeded at a concentration of 2 × 104 cells/well in 96-
well plates in standard expansion medium for 24 h. PBS was used to 
wash cells and different concentrations of LBN or Lipofectamine 2000 
were used to treat cells for 6 h. Cell viability was evaluated using the 3-
(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay. MSCs were incubated with MTT solution (5 mg/ml, 20 μl, Sigma, 
USA) for 4 h. After the supernatant was discarded, dimethyl sulfoxide 
(DMSO, 300 μl) was used to dissolve the formazin crystals. Biotek plate 
reader was used to quantify cell viability by measuring absorbance at 570 
nm. 
3.2.10 LBN internalization  
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  LBN was prepared using carboxyfluorescein-labeled DOPE and 
the rhodamine labeled pDNA. The rMSCs were incubated in 96-well 
plates at 37 ° C. The cells were then transfected with dye-labeled LBN 
and incubated for 4 h. The transfection medium was then replaced with 
fresh expansion medium. MSCs were later fixed with 4% 
paraformaldehyde for 20 mins. Cell nuclei were stained with DAPI. The 
LBN particle internalization was visualized with fluorescence microscope. 
3.2.11 Gene transfection 
Dulbecco’s Modified Eagles Medium (DMEM) containing 15% 
fetal bovine serum (FBS) and 1% antibiotic was prepared as expansion 
medium for rMSCs and rat dermal fibroblasts. Cells were cultured in the 
24-well plate at a density of 1 × 105 cells/well and incubated for 24 h. 
Cell culture medium was replaced with 500 l fresh expansion medium 
and various LBN particles were added with a final 1 g/ml DNA per well. 
Lipofectamine 2000 was used as a control. The cells were incubated for 
another 4 h at 37°C. The transfection medium was then replaced with a 
fresh expansion medium. GFP expression was visualized with fluorescent 
microscopy. For flow cytometry evaluation (Becton-Dickinson 
Biosciences, Franklin Lakes, NJ, USA), the transfected cells detached 
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from culture flasks by trypsin digestion and fixed in 4% 
paraformaldehyde for 20 min to prepare single cell suspensions.  
3.2.12 Immunofluorescence assay 
4% fresh paraformaldehyde was used to fixed rMSCs for 40 min at 
room temperature. Then PBS was used to wash the cells, followed by 
incubation of the cells for 1 h in blocking buffer (5% goat serum, 1% 
BSA, 0.1% Triton X-100 in PBS). After the blocking buffer was removed, 
the cells were incubated overnight at 4°C in the presence of primary 
antibody (VEGF, rabbit, abcam) diluted in PBS (5% goat serum). Then 
PBS was used to wash the cells. The cells were then incubated with the 
dye-labeled antibody, goat anti-rabbit IgG-TRITC (1:250, Santa Cruz 
Biotechnology) in PBS (5% goat serum), without light at room 
temperature for 2 h. After the cells were washed, they were stained with 
DAPI (0.5 g/mL, Invitrogen). A fluorescence microscope was then used 
to image the cells.  
3.2.13 Statistical analysis 
Statistical analysis was performed using two-tailed unpaired 
Student’s t-test. Data are presented as mean ± SD (standard deviation).  
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3.3  Results and Discussions 
3.3.1 LBN particles characterization  
 LBN particles were fabricated using a packaging technique as 
described in Figure 3.1. Briefly, the negatively charged DNA, i.e., the SB 
transposon system, was condensed via electrostatic interactions with 
positively charged protamine. The DNA to protamine ratio was tuned to 
form a slightly negatively charged polyplex. The rMSC-targeting 
peptides were conjugated to 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-
PEG-MAL) lipids (Figure 3.1A). Specifically, the thiol groups on the 
cysteine residues of 3VT-peptide or VT-peptide were reduced for 
facilitating the conjugation of the targeting peptide to DSPE-PEG-MAL 
lipid. The cysteine reduction efficiency was >95% as determined by 
DTNB assay162. The conjugated anionic peptide-lipid complexes were 
later anchored onto the LBNs. The resultant peptide-lipid conjugates 
were co-inserted into DOTAP/DOPE/Chol liposomes, which were 
prepared by a thin film hydration method114,163, using a post-insertion 
technique164,165. Finally, the positively charged liposome complex was 
coupled with negative charged protamine/DNA polyplex to give rise to 





Figure 3.1   The schematic showing the construction of stem cell targeting 
lipid-based nanoparticles (LBNs). A) Thiol group of cysteine at the 
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carboxyl-terminus of targeting peptide was conjugated to maleimide 
(MAL) group of DSPE lipid to form peptide-lipid complexes. B) Peptide-
lipid complexes were co-assembled with other lipids (DOTAP, DOPE) 
and cholesterol to form cationic targeting liposome. Cationic protamine 
and NLS were collectively used to condense DNA to form anionic 
protamine/DNA/NLS polyplexs. Finally, the anionic polyplexs were 
entrapped into cationic targeting liposome to generate cationic targeting 
LBNs.   
    The dynamic light scattering of the as-prepared liposomes (with 
0% peptide-lipid insertion) showed a size of 110.37 nm with a zeta 
potential of 77.17 mV (Figure 3.2). The size of the targeted LBN (with 
10% 3VT-peptide-lipid insertion) increased to 190.24 nm, with a zeta 
potential decreased to 62.22 mV (Figure 3.2). As the molar percentage of 
peptide-lipid in LBNs increased, the size of particles increased and the 
zeta potential decreased, which indicates the successful insertion of 
peptide-lipid into the liposomes to form LBNs. The particle size and zeta 
potential of different percentages of VT-peptide-lipid in LBNs showed a 




Figure 3.2  Comparison of nanoparticle size and zeta potential between 
liposomes with different molar percentages of 3VT-peptide-lipid. Data are 





Figure 3.3  Particle size and zeta potential comparison of different 
percentages of VT-peptide-lipid in liposome. Data are shown as mean ± 
SD (n = 3). 
  The DNA loading capability of protamine was determined by gel 
retardation assay (Figure 3.4). DNA was completely encapsulated when 
the mass ratio of protamine/DNA reached 4:1. Thus 2:1 ratio was used to 
render the negative charge of protamine/DNA. DNA loading capacity of 
liposome was also evaluated (Figure 3.5). The result indicated DNA was 
completely encapsulated when liposome/DNA mass ratio reached 3:1, 
which indicated the particle was slightly positively charged. Thus, this 
ratio was used in the subsequent experiments. The positively charged 
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nanoparticle will interact with negatively charged cell surface to propel 
subsequent endocytosis uptake166,167. 
 
Figure 3.4    The DNA retardation assay to determine the DNA loading in 
protamine at various weight ratios of Protamine/DNA. (1) 0:1, (2) 
0.0625:1, (3) 0.125:1, (4) 0.25:1, (5) 0.5:1, (6) 1:1, (7) 2:1, (8) 4:1, (9) 8:1 
and (10) 16:1 respectively. Gel retardation result indicates DNA is 




Figure 3.5    Gel retardation assay of LBN at various liposome/DNA mass 
ratios.  (1) 0:1, (2) 0.1875:1, (3) 0.375:1, (4) 0.75:1, (5) 1.5:1, (6) 3:1, and 
(7) 6:1. Gel retardation result indicated DNA was completely encapsulated 
when Liposome/DNA ratio reaches 3:1 on lane 6. The mass of liposomes 
was denoted by the mass of DOTAP in LBN. 
3.3.2 Cell cytotoxicity assay  
  The cytotoxicity of as-prepared LBN was evaluated by MTT assay 
(Figure 3.6) with Lipofectamine 2000 as a control. At a concentration of 
20 μg/ml,  rMSCs viability was obviously reduced below 60% with 
Lipofectamine treatment, whereas all rMSCs remained above 80% 
viability when treated with different LBN particles. The results clearly 
demonstrated that our LBN particles are more biocompatible than 
Lipofectamine. Actually, LBN with a concentration of only 3 μg/ml was 




Figure 3.6  MTT assay of MSCs at different concentrations of LBN 
particles and Lipofectamine 2000. Data are shown as mean ± SD (n = 3). 
3.3.3 Cell internalization of LBN 
  After the successful synthesis of LBN with low toxicity and high 
DNA-loading capability, we performed cell internalization of LBN in 
rMSCs (Figure 3.7). To verify the capability of internalization of LBNs 
in rMSCs due to the presence of rMSC-targeting peptide on the surface, 
green dye-labeled lipids and red dye-labeled DNA were used to form 
LBNs, followed by interaction with rMSCs. Green fluorescence from 
carboxyfluorescein-labeled liposome and red fluorescence from 
rhodamine-labeled DNA demonstrated that the LBNs were successfully 
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internalized in rMSCs. LBNs with targeting 3VT-peptide showed higher 
fluorescence than those without targeting peptide (Figure 3.7). This result 
indicated that targeting peptides facilitated the cellular internalization of 
LBNs. Thus the rMSC-targeting peptides on the surface of LBNs 
facilitated the internalization of LBN in rMSCs, which could lead to 
enhanced gene delivery to rMSCs. 
 
Figure 3.7   Fluorescent images of rMSCs after internalization of LBN 
with and without 3VT-peptide for 4 h. Lipids, DNA and cell nuclei were 
labeled with a green dye (carboxylfluorescein, a and a’), a red dye 
(rhodamine, b and b’) and DAPI (c and d’), respectively. d is a merged 
version of a, b and c.  d’ is a merged version of a’, b’ and c’.  
3.3.4 Gene transfection 
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  The LBNs containing EGFP-VEGF plasmid and rMSCs-targeting 
peptide were investigated for targeted gene transfection to rMSCs in 
vitro. The quantitative EGFP expression was determined by flow 
cytometry. To determine the optimal gene transfection efficiency of 
LBNs, various percentages of VT-peptide-lipid (VT-lipid) or 3VT-
peptide-lipid (3VT-lipid) in LBNs (without NLS peptide) were evaluated 
(Figure 3.8A). As the percentage of peptide-lipid increased, the gene 
transfection efficiencies also increased. At 5% of VT-lipid or 3VT-lipid, 
the transfection efficiencies plateaued at around 26% or 33%. So 5% VT-
lipid or 3VT-lipid was used for the subsequent experiments. The plateau 
of transfection efficiency might result from the more negative zeta 
potential of LBN with an increased percentage of peptide-lipid in LBNs, 
since more negative zeta potential of the nanoparticles will not favour 
cell internalization. The effect of varying NLS peptide/DNA mass ratio 
on transfection efficiencies was also monitored with 5% 3VT-lipid 
prepared liposome. A 2:1 peptide/DNA ratio resulted in the highest gene 





Figure 3.8  Effect of rMSC-targeting and NLS peptides on the 
transfection efficiency in rMSCs by LBN. A) The EGFP transfection 
efficiency of LBN with various molar percentages of peptide-lipid. 
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Asterisk denotes p < 0.05 comparing transfection efficiency of 3VT-
peptide-lipid with VT-peptide-lipid at same percentage of peptide-lipid. B) 
The EGFP gene transfection efficiency of LBN with various NLS 
peptide/DNA mass ratios. EGFP gene expression was evaluated after 72 h 
transfection. Data are shown as mean ± SD (n = 3).  
  Transfection efficiencies of various LBNs were evaluated (Figure 
3.9A). The corresponding EGFP gene expression was visualized with 
fluorescence microscopy (Figure 3.9B). We find that LBN particles 
without the surface display of the peptides (13.64%) showed similar 
transfection efficiency compared with commercially available 
Lipofectamin 2000 (14.65%). However, when displaying VT-peptide, 
LBN particles exhibited enhanced transfection efficiency (25.64%). 
Moreover, LBNs with 3VT-peptide (32.57%) demonstrated even higher 
transfection efficiency in comparison to those with VT-peptide. 
Importantly, when LBNs bear both 3VT-peptide and NLS peptide, the 
highest level of transfection (52.52%) was reached. Our results clearly 
indicated that both VT-peptide and 3VT-peptide facilitated LBN to 
efficiently deliver plasmid gene into MSCs. The three-fold reiterated 
3VT-peptide demonstrated significantly enhanced transfection efficiency 
compared with VT-peptide. The targeting peptide and NLS peptide 







Figure 3.9    Comparison of transfection expression of EGFP in rMSCs by 
different carriers in 72 h.  A)  EGFP expression determined by  different 
carriers: (a) Lipofectamine® 2000 (control), (b) LBN without any peptide, 
(c) LBN with control peptide CGVKYMVM, (d) LBN with VT-peptide, 
(e) LBN with 3VT-peptide, (f) LBN with NLS peptide, (g)  LBN with VT-
peptide and NLS peptide, and (h) LBN with 3VT-peptide and NLS peptide. 
Data are shown as mean ± SD (n = 3). Asterisk denotes p < 0.05.  B) 
Fluorescence microscopy showing EGFP expression in rMSCs by carriers 
shown in A. Image 1 and 2 in (a–h) show the bright-field image and green 
EGFP expression, respectively.  
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  To evaluate the specificity of LBN particles, rat dermal fibroblasts 
were used as a control cell for gene transfection (Figure 3.10). Flow 
cytometry results showed low transfection efficiency and no significant 
difference between LBNs with (3.34%) and without targeting peptide 
(3.97%). The results indicated that LBN with rMSCs-targeting peptide 
has no specificity for rat dermal fibroblasts.  
 
Figure 3.10   Transfection efficiencies of LBN with and without 3VT-
peptide on rat dermal fibroblasts were evaluated with flow cytometry (A) 
and fluorescence microscopy (B).  Data are shown as mean ± SD (n = 3).  
 
  A time course assessment of gene expression was carried out to 
compare EGFP-encoding SB transposon system for up to 168 h (Figure 
3.11). The expression of EGFP in both EGFP-encoding SB transposon 
system and traditional (control) EGFP-encoding plasmid (pEGFP-N1) 
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reached maximum at 72 h. However, the transfection efficiency of 
control EGFP plasmid later decreased substantially at 168 h. In 
comparison, the SB system maintained a high transfection level even at 
168 h. This result demonstrated the stable and durable gene transfection 
effect of SB system due to the efficient integration of target gene into 
rMSCs host genome by the transposase in the SB system.  
 
Figure 3.11   Time course comparison of gene expression of SB 
transposon system and control EGFP plasmid showing the long-lasting 
EGFP gene expression delivered in the form of SB transposon system.  
EGFP expression level of SB transposon system in rMSCs reached a 
maximum in 72 h, which was set as 100%. Data are shown as mean ± SD 
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(n = 3). Asterisk denotes p < 0.05 comparing with maximum expression at 
72 h.   
   Studies indicated that VEGF gene delivery to MSCs improved 
therapeutic function of MSCs.168-171 The strategy for constructing EGFP-
VEGF-encoding SB transposon system was shown in Figure 3.13. After 
LBNs carrying the SB transposon system were used to transfect rMSCs, 
immunofluorescence assay was performed to visualize the VEGF gene 
expression (Figure 3.12) after 144 h of expression. When rMSCs were 
transfected with EGFP-VEGF-encoding SB transposon system, high 
transfection efficiency and co-expression of EGFP and VEGF were 
observed. In comparison, only EGFP gene expression but no VEGF 
expression was monitored when control EGFP-encoding SB transposon 
system was used. This result demonstrated the feasibility of using the 




Figure 3.12    Comparison of gene expression of EGFP-VEGF or EGFP in 
SB transposon system by immunofluorescence assay. EGFP gene 
expression showed green fluorescence. VEGF gene expression was 
marked with red fluorescent tetramethylrhodamine (TRITC) labeled 
antibody. Cell nucleus was labeled with blue DAPI. LBN with 3VT-











Figure 3.14    A stem cell targeting particle directed targeted gene 
delivery. This scheme shows the lipid-based nanoparticles (LBNs) 
endocytosis and gene expression mechanism. LPD particle enters MSCs 
through receptor mediated endocytosis. In cell cytoplasm, polyplex is 
released from endosome. Polyplex enters cell nucleus through NLS 
mediated nuclear transport. In cell nucleus, DNA is released and 
transcribed. In the end, gene is translated to protein in cell cytoplasm.  
 3.4  Conclusion 
  In summary, we developed a LBN system by incorporating the 
targeting peptides, NLS peptides and a VEGF-encoding SB transposon 
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system172. The resultant targeting LBN demonstrated high gene 
transfection efficiency and sustained gene expression profile, due to 
improved MSCs-internalization, nuclear translocation and gene 
integration. The gene delivery and gene expression mechanism was 
shown in Figure 3.14. The three-fold reiterated targeting peptide showed 
much higher capability in improving the transfection efficiency in stem 
cells than the non-reiterated targeting peptide. Targeting peptide and NLS 
peptide as well as the use of SB transposon system exerted a synergetic 
effect to promote efficient and lasting transfection gene expression. The 
LBNs are shown to efficiently deliver VEGF-encoding SB transposon 
system into stem cells to enable the cells to efficiently produce VEGF.  
This targeting LBN complex may have promising applications in clinical 




Chapter 4 Virus Mimetic Cytoplasm Cleavable 
Magnetic/Silica Nanoclusters for Enhanced Gene Delivery 
to Mesenchymal Stem Cells 
4.1  Introduction 
Development of non-viral gene delivery vectors for transfecting 
MSCs will advance the tissue engineering and regenerative medicine to 
treat several health disparities associated with the heart, brain, spinal cord, 
bone, and blood vessels.173-175 In the last decade, there has been 
remarkable progress in regenerative medicine using the stem cells for 
therapeutic applications.176 However, to use these cells more effectively, 
enabling them to express functional proteins is crucial for rapid formation 
and repair of tissues and organs. For example, vascular endothelial 
growth factor (VEGF) is essential for angiogenesis for the progression of 
new blood vessels. Indeed, efficient VEGF gene expression in 
mesenchymal stem cells (MSCs) can stimulate the formation of new 
blood vessels. However, the transfection of VEGF gene into stem cells is 
complex and challenging because stem cells are hard to transfect. 
Hitherto, the most efficient gene delivery vectors used in MSCs are 
genetically engineered viruses encompassed with gene of interest.177-179 
The major limitations in using viral vectors are their inherent toxicity and 
101 
 
ability to induce immune and inflammatory responses. This fact drives 
research on the development of biocompatible non-viral vectors such as 
cationic lipids, polymers, hydrogels, and synthetic nanoparticles 
(NPs).180-186 But these non-viral vectors are less effective when compared 
with viral vectors mainly due to the lack of efficient homing and 
internalization of foreign genes. So there is an urgent need in regenerative 
medicine to develop safe and efficient non-viral vectors for delivering a 
foreign gene to MSCs. 
4.2   Materials and Methods 
4.2.1  Materials 
All commercial chemicals and reagents used in this research are 
used as received without any further purification. Iron (III) 
acetylacetonate, 1,2-dodecanediol, oleic acid, oleylamine, benzylether, 3-
aminopropyltrimethoxysilane, 3-mercaptopropyltrimethoxysilane, 
tetraethylorthosilicate, hexadecyltrimethylammonium bromide (CTAB), 
penicillin-G, and streptomycin were all purchased from Sigma Aldrich. 
Fetal bovine serum (FBS), Lipofection 2000, and primers for PCR were 
purchased from Invitrogen. DMEM media was purchased from Gibco-
BRL. LongAmp® Taq PCR Kit was purchased from NEB Inc. 
4.2.2   Hydrophobic magnetic nanoparticles synthesis 
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10 nm hydrophobic magnetic nanoparticles were synthesized by the 
seed mediated growth method. First, 4 nm Fe3O4 nanoparticles were 
synthesized by the dissociation of 2 mmol of Fe(AcAc)3 in 10 mmol of 
1,2-dodecanediol, 6 mmol of oleic acid, 6 mmol of oleylamine and 20 ml 
of benzyl ether. The reaction mixture was in reflux (300oC) under 
nitrogen atmosphere for 1 h. The synthesized nanoparticles were washed 
several times with ethanol to remove the un-reacted chemicals and finally 
the precipitated nanoparticles were separated with a magnet. The same 
procedure was repeated to synthesize the 6 nm and 10 nm nanoparticles 
by dissolving the 4 nm and 6 nm seed nanoparticles in hexane, 
respectively. 
4.2.3   MSNCs Synthesis 
The GSH-cleavable MSNCs were synthesized by in situ hydrolysis 
of tetraethyl orthosilicate (TEOS) and (3-
mercaptopropyl)trimethoxysilane (MTMS) in the presence of 
superparamagnetic iron oxide nanoparticles (SPIOs) dispersed in Cetyl 
trimethylammonium bromide (CTAB) at 70 oC for 1 h. The excess CTAB 
present in the reaction medium was completely removed by 
centrifugation at 10,000 rpm for 10 min for three times and re-suspended 
in nanopure water. After complete removal of CTAB, the nanoparticles 
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solution was aged for 48 h, which resulted in the formation of 80-100 nm 
spherical MSNCs. 
4.2.4   DNA Loading 
As-synthesized MSNCs were centrifuged three times to remove 
excess surfactants, then the purified nanoparticles (8 µg/ml) were 
incubated overnight at 4oC with 2 μg of DNA before modified with 
protein conjugated PEI. We have confirmed the successful DNA loading 
using gel electrophoresis. 
4.2.5  Transmission Electron Microscope 
Magnetic silica nanoparticles were analyzed in a TEM (JEOL-
2000FX). One drop of nanoparticles of each type was placed on a dry 
carbon-coated copper grid (150 mesh). 
4.2.6   Dynamic light scattering (DLS) 
The size distribution of MSNCs was measured using DLS in 
nanopure water. Our result shows that the average hydrodynamic size of 
MSNCs is ~150 nm.   
4.2.7   DTNB assay 
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DTNB assay was performed as previously described 187. 4 mg/ml 
5,5'-Dithiobis- 2-nitrobenzoic acid (DTNB) solution was prepared in 
ethanol. 8 ug/ml VMSNCs were treated with 1 mM or 0.1 mM GSH. At 
predetermined time intervals, the reaction solution (200 ul) is centrifuged 
to remove GSH in solution. The pellets were resuspended in PBS and 
incubated with DTNB solution (4 ul) for 5 min at room temperature. The 
absorbance was measured at 412 nm and free thiol concentration was 
calculated. 
4.2.8    Gel retardation assay  
MSNCs were loaded with 0.25 µg of DNA, which is confirmed 
using gel electrophoresis as shown in Figure 4.8 (1% agarose gel (105V) 
with ethidium bromide staining). 
4.2.9    DNA release assay 
  In vitro release of the DNA from VMSNCs with or without 
glutathione (GSH). 1 ml of 8 ug/ml VMSNCs were incubated with 5 ug 
DNA for 6 h at room temperature. DNA loaded VMSNCs were collected 
by centrifugation for 20 min at 13000 rpm. MSNCs pellets were 
resuspended in PBS and incubated with 1 mM GSH. DNA loaded 
VMSNCs without GSH treatment were used as control.  At 
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predetermined time intervals, the nanolusters suspension were 
centrifuged and the amount of DNA released in the supernatant was 
determined by spectrophotometry at 260 nm. 
4.2.10    MTT Assay 
The cells were plated at a density of 4 × 103 cells/well in 96-well 
plates in standard growth medium for 24 h. They were then washed twice 
in PBS and treated with different concentrations of magnetic silica 
particles for 72 h. The measurement of cell viability was carried out using 
the 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay. MTT was used as an indicator of cell viability as determined by its 
mitochondrial-dependent reduc¬tion to formazin. Cells were incubated 
with MTT (5 mg/ml, 20 μl/well, Sigma, USA) in cell culture for 4 h. 
Finally, the supernatant was removed, followed by the addition of 
dimethyl sulfoxide (DMSO, 150μl/well, Sigma, USA) and agitated for 10 
min to dissolve the formazin crystals completely. The optical density was 
measured at an absorption maximum of formazin at 570 nm on a Biotek 
plate reader. 
4.2.11    Zeta potential (ξ) 
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The surface charge of the nanoparticles was measured by the zeta 
potential in nanopure water using a Zeta pal instrument. 
4.2.12    Isolation of major coat protein (pVIII) from phage 
We followed a reported procedure188 to purify pVIII from MSC-
targeting phage selected by us previously189 where pVIII bears MSC-
targeting peptide. Equal volumes of Tris-HCl and saturated phenol (pH 
8.0) were added to the solution of phage virions. The solution was mixed 
by vigorously shaking for 8 min; then centrifuged for 10 min at a speed 
of 3000g. After centrifugation, the aqueous supernatant containing phage 
DNA was removed and transferred to another tube. The same procedure 
was repeated 4 more times by adding 1 vol. of Tris-HCl (pH 8.0) to the 
phenol phase obtained in the previous step to remove the phage DNA 
completely. The obtained phage protein in phenol was diluted with 2 vol. 
of methanol and dialyzed against a 1:1 mixture of methanol and 10 mM 
Tris-HCl (pH 8.0), a 1:3 mixture of methanol and 10 mM Tris-HCl (pH 
8.0), only 10 mM Tris-HCl (pH 8.0), and deionized water for 12 h for 
each dialysis step. Finally, 1 ml PBS was added to the pure phage protein 
and stored at -20oC for further experiments.   
4.2.13    VMSNCs Synthesis 
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The 1 mM of isolated MSC-targeting pVIII protein was conjugated 
to the surface of the 1 nM MSNCs to obtain VMNCs. Bio-conjugation 
was carried out by protecting the –NH2 groups using 2 mM of tert-Butyl 
carbamate (BOC) in THF/H2O, which was important to stop the self-
conjugation of pVIII. The –COOH groups present in pVIII protein were 
activated using 2 mM of 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride and N-
Hydroxysuccinimide (EDC/NHS). Then the activated pVIII protein was 
incubated with amine terminated PEI on DNA-loaded MSNCs for 4 h in 
a buffer at pH 7.5.  
4.2.14    MTT Assay 
The cells were plated at a density of 4 × 103 cells/well in 96-well 
plates in standard growth medium for 24 h. They were then washed twice 
in PBS and treated with different concentrations of magnetic silica 
particles for 72 h. The measurement of cell viability was carried out using 
the 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) assay. MTT was used as an indicator of cell viability as 
determined by its mitochondrial-dependent reduction to formazin. Cells 
were incubated with MTT (5 mg/ml, 20 μl/well, Sigma, USA) in cell 
culture for 4 h. Finally, the supernatant was removed, followed by the 
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addition of dimethyl sulfoxide (DMSO, 150μl/well, Sigma, USA) and 
agitated for 10 min to dissolve the formazin crystals completely. The 
optical density was measured at an absorption maximum of formazin at 
570 nm on a Biotek plate reader. 
4.2.15    Gene transfection 
MSCs at the third passage were washed with PBS and detached by 
incubation with 0.25% trypsin-EDTA for 2 to 3 min at 37°C. Complete 
medium was added to inactivate the trypsin. The cells were centrifuged at 
1000g for 3 min, the medium was removed, and the cells were re-
suspended in 2 to 5 ml of complete medium. The cells were counted 
using a hemacytometer and then plated at a density of 1 × 104 cells/well 
(24 wells plate) for overnight culturing. Then the cells were treated with 
different concentrations of VMSNCs complexed with DNA (eGFP-
VEGF) and MSC-targeting pVIII in the medium without FBS with or 
without an external magnetic field. After 4 h incubation, the treated 
solution was removed and then added to the culture medium with FBS. 
The cells were checked with a fluorescence microscope (Nikon) at the 
indicated time for the expression of reporter gene.  
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4.3 Results and discussion 
4.3.1 VMSNCs synthesis and characterization 
Here, for the first time we demonstrated the virus mimetic magnetic 
silica nanoclusters (VMSNCs) for gene delivery to MSCs (Figure 4.1). 
The VMSNCs are designed on the following observations. First, fd-tet 
phage is a virus that specifically infects bacteria by transferring DNA to 
cells and is non-toxic to human beings. It is made of DNA encapsulated 
by a protein coat (Figure 4.1). The protein coat includes ~3900 copies of 
major coat protein (pVIII) on the side wall of phage and ~5 copies each 
of four minor coat proteins at the two tips of phage.190 We have recently 
used phage display technique to discover fd-tet phage particles that 
display a MSC-targeting peptide (VTAMEPGQ) as fusion to each of 
~3900 copies of pVIII constituting the side wall of phage.191 We also 
found that the MSC-targeting peptide could promote the delivery of the 
gene into MSCs once presented on liposome NPs. Second, embedding 
superparamagnetic iron oxide (SPIO) NPs in a silica matrix can aid 
magnetically guided gene delivery, which is crucial for future in vivo 
applications. Third, porous structure formed due to the aggregation of 
SPIO and silica NPs in the nanoclusters through S-S bonds (Figure 4.2) 
can safely hold and protect DNA before gene release and expression. 
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Fourth, pVIII can be purified from fd-tet phage body,192 and then 
chemically conjugated with PEI to ensure the targeting of the cluster to 
MSCs. Lastly, once the cluster is internalized in the MSCs, the S-S bonds 
holding the NPs together in the cluster can be cleaved by intracellular 
glutathione (GSH) (Figure 4.2E) to dissociate the nanocluster, leading to 
the DNA release and gene expression for improved gene transfection. 
The VMSNCs mimic phage structure by bearing phage-borne pVIII on 
the surface and loading DNA inside, can promote their cell-
internalization and gene transfection to MSCs. 
 
Figure 4.1   Virus Mimetic Magnetic Silica Nanoclusters (VMSNCs) for 
gene delivery to MSCs. The MSC-targeting phage particle has ~3900 
copies of pVIII with the MSC-targeting peptide fused to the solvent-
exposed terminal. The MSC-targeting pVIII can be isolated and purified 
from the phage. Cleavable MSNCs are synthesized by embedding SPIO 
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NPs in silica network, which is achieved by in situ hydrolysis of tetraethyl 
orthosilicate (TEOS) and (3-mercaptopropyl)trimethoxysilane (MPTS) in 
the presence of SPIO NPs dispersed in Cetyl trimethylammonium bromide 
(CTAB). Then the DNA (red circles) is incorporated into the porous 
structure of SPIO-embedded silica matrix. The magnetic silica 
nanoclusters (MSNCs) are modified with polyethyleneimine (PEI), which 
is conjugated with pVIII (blue) purified from MSC-targeting phage by 
EDC/NHS chemistry, to form VMSNCs. Bearing phage-borne pVIII on 
VMNSCs allows the clusters to mimic phage particles, target and enter 
MSCs to achieve gene delivery. The successful transfection of MSCs 
using VMSNCs is visualized by green fluorescence from eGFP. 
These GSH-cleavable MSNCs were formed by in situ hydrolysis of 
TEOS and MPTS in the presence of hydrophobic SPIO NPs dispersed in 
CTAB. The spherical magnetic silica nanoclusters (MSNCs, Figure 4.2A, 
4.2B, 4.2D) were synthesized with a diameter of ~80-100 nm. 
Transmission electron microscopy (TEM) images (Figure 4.2A, 4.2B) 
clearly verify the magnetic NPs embedded in a silica matrix to form a 




   
 
Figure 4.2    MSNCs synthesis mechanism and characterization. (A)  
TEM image of MSNCs showing the magnetic NPs embedded in silica. (B) 
High magnification image of an individual nanocluser to show the 
intrinsic pores inside the cluster (pointed with arrows). (C) TEM images of 
GSH treated MSNCs, which shows the clusters were dissociated due to the 
cleavage of S-S bonding between the NPs inside nanoclusters, white 
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arrows indicates the partially dissociated nanoclusters. (D) Scanning 
electron microscope (SEM) image of MSNCs to show the large view and 
morphology of clusters. (E) Mechanism of magnetic/silica nanocluster 
(MSNC) formation and their subsequent cleavage by oxidation/reduction 
mechanism of sulfhydryl bonds between the silica/Fe3O4 NPs. Specifically, 
Fe3O4 NPs are embedded inside a porous matrix aggregated from silica 
NPs through S-S bond. The resultant cluster is porous and can hold loaded 
DNA. In the presence of intracellular GSH, the S-S bond will be broken to 






Figure 4.3   FT-IR spectra of PEI modified magnetic/silica nanoclusters. 





Figure 4.4   Energy dispersive X-ray microanalysis spectrum of 
nanoclusters measured in JEOL JSM880. Inset shows the approximate 
elemental composition of Si and Fe at the selected area. 



















Figure 4.5   Dynamic light scattering (DLS) hydrodynamic size 
distribution of MSNCs showing an average size of ~150 nm. 
During the in situ hydrolysis of TEOS and MTMS in the presence 
of hydrophobic SPIO NPs, upon aerial oxidation, S-S bonding between 
the formed thiolated silica colloidal NPs tend to aggregate into MSNCs 
while the hydrophobic SPIO NPs are being embedded inside the resultant 
clusters. The inter-particle S-S bonding in the nanoclusters was 
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confirmed by the fact that incubating the nanolusters (10 nM) in 5 mM 
GSH for 4 h at 37oC dissociated the nanoclusters into isolated NPs. TEM 
images (Figure 4.2A, C) clearly show the particle difference before and 
after GSH treatment, which confirms the presence of S-S bonding and 
subsequent cleavage upon GSH reduction. The intracellular GSH 
concentration (1-10 mM) is significantly higher than extracellular levels 
(2-20 uM)193,194, providing a mechanism for controlled intracellular 
release. DTNB assay is used to measure free thiol concentration of 
VMSNCs in the presence of GSH concentrations at 1 mM and 0.1 mM 
(Figure 4.6).  The addition of GSH triggered the release of free thiol, 
confirming that cellular GSH can indeed cleave the disulfide bond to 
release DNA. These kinds of thiol-fused MSNCs can be used as 
molecular switches for triggered release of therapeutics in cytoplasm by 
reducing the inter-particle disulfide bonding in the presence of GSH 




Figure 4.6   Time course of in vitro free thiol release from 8 ug/ml 
VMSNCs in the presence of GSH concentrations at 1 mM and 0.1 mM. 
The addition of GSH triggered the release of free thiol. The profile in the 
figure exhibited a rapid thiol release, due to enhanced VMSNCs 
dissociation in the presence of a high concentration of GSH (1mM). In 
contrast, the thiol release is relatively slow at a low GSH concentration 
(0.1 mM).  
Magnetic measurement at 300 K using a magnetometer195 showed 
that both SPIO NPs and MSNCs were superparamagnetic (Figure 4.7). 
However, the paramagnetic strength of clusters was determined to be 4.0 
Am2/kg at 1.0 tesla, which is 10 folds lesser than SPIO NPs. This is 
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mainly due to the weight percentage of SPIO NPs present in MSNCs. 
The magnetic measurement confirmed the superparamagnetic nature of 
our nanoclusters, which is crucial for magnetically guide the delivery of 
the gene-loaded nanoclusters into cells (magnetofection). 
 
Figure 4.7    Magnetic Properties: Hysteresis loops of SPIO (straight line) 
and cleavable MSNCs (dotted line) measured in SQUID. Inset shows the 
magnetic strength of the MSNCs in water with (left) and without (right) a 
magnetic bar. 
4.3.2 DNA loading capacity 
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The DNA loading capability of the MSNCs before modification 
with PEI was estimated by gel electrophoresis. Figure 4.8 shows DNA is 
completely encapsulated at NP/DNA ratio 1:1. In fact, only 2 µg of DNA 
was used to complex with 8 ug/ml of MSNCs for transfection studies in 
MSCs in this work. These MSNCs were further modified with low 
molecular weight PEI (MW= 8 kDa). The FTIR spectrum (Figure 4.3) 
confirms the presence of PEI, SiO2, and Fe3O4 in the nanoclusters. The 
zeta potential of the PEI modified MSNCs was determined to be 26±2 
mV. This positive charge will promote the efficient gene transfection.  
 
Figure 4.8   The DNA retardation assay of DNA loading in nanoparticles 
at various weight ratios of NP/DNA. (1) 0:1, (2) 0.015625:1, (3) 0.03125:1, 
(4) 0.0625:1, (5) 0.125:1, (6) 0.25:1, (7) 0.5:1, (8) 1:1 and (9) 2:1 
respectively. 0.25 ug DNA is used per lane. Gel retardation result indicates 
DNA is completely encapsulated at NP/DNA ratio 1:1 on lane 8. 
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The pVIII was isolated from the MSC-targeting filamentous fd-tet 
phage, which was identified by us recently and had ~3900 copies of 
MSC-homing pVIII,191 by phenol extraction following a reported 
protocol.192 The MSC-homing pVIII purified from the MSC-targeting 
phage can favor the MSC-homing of the NPs modified with the pVIII. 
Towards this end, the isolated pVIII is conjugated to the PEI on the 
surface of the nanoclusters so that the nanoclusters can home to MSCs. 
Bio-conjugation between the C terminal end of pVIII and –NH2 in PEI 
was carried out using 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide 
hydrochloride and N-Hydroxysuccinimide (EDC/NHS) conjugation 
chemistry. The resultant VMSNCs exhibited both magnetic and 
fusogenic properties. 
4.3.3 Cleavage of VMSNCs and DNA release  
A DTNB assay was used to measure the concentration of thiol 
groups present in NPs formed owing to the cleavage of VMSNCs in the 
presence of GSH with a concentration of 1 mm or 0.1 mm (Figure 4.9). 
The addition of GSH triggered the cleavage of disulfide bond in the 
nanoclusters and the concurrent formation of free thiol groups (Figure 
4.9), suggesting that thiol-fused MSNCs can be used as molecular 
switches for triggered release of therapeutics in cytoplasm by reducing 
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the interparticle disulfide bonding in the presence of GSH available in the 
living cells. 
 
Figure 4.9   Time course of the concentration of free thiols present on the 
nanoparticles as a result of the cleavage of disulfide bonds in VMSNCs by 
GSH at 1 mM and 0.1 mM. The addition of  GSH triggered the cleavage 
of disulfide bond to form free thiol groups. The profile shows that thiol 
groups are formed over time and then level off after 60 min at 1 mM GSH, 
and a higher GSH concentration promoted the formation of free thiol 
groups (and thus the cleavage of nanoclusters). 
We later examined DNA release from VMSNCs in the presence and 
absence of GSH at physiological concentration (1mM) (Figure 4.10). Our 
data showed that GSH-treated VMSNCs demonstrated sustained release 
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of DNA whereas the VMSNCs in the absence of GSH showed minimum 
DNA release. The results suggested that GSH at an intracellular 
concentration can cleave the disulfide bond in the VMSNCs and 
consequently lead to the release of DNA from the nanoparticles.  
 
 
Figure 4.10      GSH-treated VMSNCs demonstrated a sustained release of 
DNA. 2.27 ug of DNA was released in the first 4 h and 3.07 ug DNA was 
released in 12 h. VMSNCs without GSH treatment in the absence of GSH 
shows significantly lower DNA release. 




(MTT) assay was done to evaluate cytotoxicity at different concentrations 
of VMSNCs. At a concentration of 20 ug/ml, VMSNCs still showed high 
cell viability at around 96% (Figure 4.11). However, lipofectamine 2000 
at the same concentration showed less than 70% cell viability (Figure 
4.12). This fact shows that VMSCNs are more biocompatible than the 
widely-used commercial transfection reagent (lipofectamine 2000). 
    
Figure 4.11   Cell viability studies: MTT assay of MSCs at different 
concentrations of VMSNCs. Bars 1 to 4 shows the % viability of MSCs 
with 10, 20, 40, and 80 ug/ml of nanoclusters in 500 µl of Fetal bovine 
serum (FBS) free Dulbecco's Modified Eagle Medium (DMEM) incubated 
for 4 h, respectively. Bar 5 is the control cells viability. After incubated 
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with nanoclusters for 4 h, cells were washed twice with PBS and fresh 
DMEM medium with 10 % FBS was added.  
 
Figure 4.12    Cell viability studies: MTT assay of MSCs at different 
concentrations of lipofectamine 2000. MSCs were treated with different 
concentration of lipofectamine in 500 µl of Fetal bovine serum (FBS) free 
Dulbecco's Modified Eagle Medium (DMEM) incubated for 4 h. Cell 
viability is reduced below 80% at 10 µg/ml lipofectamine. 
4.3.5   Cell internalization 
After the successful synthesis of desired VMSNCs with low toxicity, 
high gene loading capability and sufficient paramagnetic strength, we 
conducted cell internalization studies in MSCs (Figure 4.13). The 
VMSNCs with FITC-labeled DNA loaded were incubated with MSCs at 
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37oC. After incubation for 2 h, the cells were washed three times with 
PBS. Green fluorescence images confirmed that the VMSNCs were 
successfully internalized in MSCs. Our previous studies showed that a 
pVIII with cell-targeting peptide fused to its N-terminal could facilitate 
the cell-internalization of phage particles that bear the same pVIII.196 
Thus the internalization of VMSNCs in MSCs might be promoted by the 
MSC-homing pVIII on the surface of VMSNCs, which would facilitate 
the delivery of gene to MSCs.  
    
 
Figure 4.13   Internalization studies of VMSNCs carrying a dye-labeled 
DNA. All images were captured at 40X optical zoom. (A) Green 
fluorescence of FITC-labeled DNA entrapped in nanoclusters in MSCs to 
confirm the cell internalization capabilities of VMSNCs. (B) DAPI-
stained MSCs to show the cell nuclei. (C) Merged images of A and B. 
4.3.6  Gene transfection 
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The VMSNCs containing eGFP-VEGF plasmid and cell-targeting 
pVIII were dispersed in 500 µl of DMEM to transfect the MSCs in vitro. 
After 24 h of incubation, eGFP-VEGF gene was successfully delivered to 
MSCs by VMSNCs and expressed (Figure 4.14). The gene expression 
was visualized with the reporter eGFP gene expression by green 
fluorescence (Figure 4.14A). The quantitative eGFP expression is 
evaluated by flow cytometry (Figure 4.14B). We tested the transfection 
efficiency of VMSNCs at different transfection conditions (with or 
without pVIII or magnetic field), with lipofectamine 2000 as a control. 
The transfection efficiency of our novel cleavable VMSNCs was 
significantly better than the commercially available transfection reagent 
lipofectamin 2000 (7.66%). VMSNCs in the presence of magnet (at a 1.0 
Tesla external magnetic field) shows highest levels of transfection 
(40.01%) compared to VMSNCs in the absence of magnet (25.80%), 
MSNCs in the presence of magnet (14.64%), and MSNCs alone (6.05%). 
When control nanoparticles (MSNCs without any protein or with wild-
type pVIII modified) are used, the transfection efficiency is very low 
(less than 10%) and similar to that by lipofectamine.  . Our results clearly 
indicate that both MSCs homing phage protein and magnetic strength 
help the VMSNCs to carry the eGFP-VEGF gene into MSCs. At the 
same time, in the absence of the magnet VMSNCs transfection efficiency 
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is lower than the presence of the magnet, possibly due to the faster 
internalization and lower endosomal DNA degradation in the presence of 





Figure 4.14    Effect of the magnetic field and MSC-homing pVIII protein 
on eGFP-VEGF gene transfection in MSCs. Lipofectamine 2000 was the 
control. A) Comparison of transfection expression of EGFP (a) 
Lipofectamine 2000. (b) Transfection with MSNCs in the absence of 
magnetic field. (c) Transfection with MSNCs (i.e., the clusters with no 
pVIII on the surface) under 1T magnetic field. (d) The VMSNCs had 
MSC-homing pVIII with magnetic field. (e) The VMSNCs with wild-type 
phage pVIII without magnetic field. (f) The VMSNCs with MSC-homing 
pVIII under 1T magnetic field. Image 1 in (a–f) is bright-field light image 
and image 2 is the corresponding fluorescence image. B) Corresponding 
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EGFP expression after transfection was examined by flow cytometry. Data 
are shown as mean ± SD (n = 3). Asterisk denotes P < 0.01 with 
Lipofectamine 2000 as a reference. (Scale bar, 50 μm.) 
4.4 Conclusion 
In summary, we developed novel VMSNCs for gene delivery to 
MSCs. We transferred the MSC-targeting pVIII from phage to 
nanoclusters to enable cell internalization. These VMSNCs are ideal gene 
therapy vectors owing to their MSC-homing capability and controlled 
release at the target site. Even in the absence of the magnetic field, the 
VMSNCs can deliver gene to MSCs at a higher efficiency than 
commercially available vectors. The dual nature of virus mimicking and 
superparamagnetism make these vectors an ideal tool for the 
magnetically guided targeted delivery and possibly an ideal contrast 





 Chapter 5 MSC-binding peptide induces osteoblastic 
differentiation of mesenchymal stem cells  
5.1  Introduction  
         In the body, stem cells reside in a special microenvironment termed 
the “niche,” which supports and regulates stem cells to maintain tissue 
homeostasis17,197. Extracellular matrix (ECM) in the niche provides 
biochemical and biophysical cues to regulate stem cell fate in a temporal 
and spatial manner198-200. Biophysical cues (such as mechanical and 
topographical properties) have been demonstrated to govern various 
cellular processes including morphology, adhesion, migration, 
proliferation and differentiation14,15,89,201-206. Biochemical cues (such as 
growth factors, cytokines and ECM molecules) have also been extensively 
explored as cellular stimuli 207-210. Peptides as biochemical cues have been 
well studied and some peptide differentiation inducers or regulators were 
identified211-215. However, how the binding affinity of a peptide influences 
stem cell differentiation is not well studied.  
           Here we show that peptides with different affinities to 
mesenchymal stem cells (MSCs), which were evolutionarily selected from 
a random peptide library by phage display technique, could show different 
capabilities in inducing the osteogenic differentiation of MSCs. To 
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achieve this goal, we employ fd filamentous bacteriophage (also termed 
phage), which is a bio-nanofiber with about 7 nm in width and 890 nm in 
length216. It is advantageous as a promising biomaterial based on the 
following facts. First, it is made of DNA encapsulated by a protein coat. 
Inserting a foreign gene into phage genome leads to the display of a 
foreign peptide as biochemical cues at high density (~3900 copies of 
major coat protein) on the side wall of phage110,217. Second, it can easily 
self-assemble into ordered biomimetic nanostructures that effectively 
mimic natural ECM fibers to provide biophysical cues189,205,218. Third, it is 
non-toxic to human cells 219,220. These unique properties enable us to use 
phage as a building block to construct matrix for regulating stem cell fate.  
           Recently we have utilized phage display technique to successfully 
select several peptide sequences including VTAMEPGQ (termed VT), 
AFNPEPGQ (termed AF) and DTPPGWDQ (termed DT) with high 
affinity to rat mesenchymal stem cells (rMSCs)189. These binding peptides 
have a degree of binding affinity of 28/51, 11/51 and 5/51, respectively. 
The degree of binding affinity is defined as the number of occurrences of a 
particular peptide displayed on a phage clone divided by the total number 
of randomly chosen phage clones displaying different peptides during 
biopanning.  These peptides hold the potential to facilitate targeted rMSCs 
delivery due to the high affinity against rMSCs 172,189. We assemble 
132 
 
phages displaying these peptides into the matrix with similar 
nanotopography and then study the effect of these different binding 
peptides on the osteogenic differentiation of rMSCs. 
5.2 Methods and experiments  
5.2.1 Phage film formation 
         Nanofibrous phage films were prepared following a layer-by-layer 
self-assembly technique developed by our group221,222. Briefly, pre-
cleaned cover glass slides were immersed into a poly-lysine solution for 
20 min, allowing for the adsorption of the first cationic poly-lysine layer 
onto the glasses. The substrates were washed with water and dried in 24-
well plates. Then a phage solution with different concentrations was added 
to form the secondary layer. This process was repeated three times. The 
phage film was terminated with a phage layer.  
5.2.2 Scanning Electron Microscopy (SEM)  
          SEM was used to evaluate the morphology of rMSCs seeded on the 
phage film. The rMSCs on the phage films were fixed with 4% 
paraformaldehyde. The cells were then dehydrated in a graded series of 
ethanol (40%, 70%, 90%, and 100%) for 20 min each. The samples were 
dried by a critical point carbon dioxide. The dried samples were sputter-
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coated with palladium later. The morphology of the phage films and the 
attached cells was imaged by SEM (Zeiss Neon). Cell surface area was 
measured using the ImageJ program with fifty cells examined in each 
experiment. 
5.2.3  MTT proliferation assay 
           3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) assay was used to evaluate proliferation. The rMSCs were cultured 
on the phage films in 96 well plates for 72 h. MTT (5 mg/ml, 15 l/well, 
Sigma, USA) was then added to MSCs and incubated at 37 o C for 4 h. 
The supernatant was removed and dimethyl sulfoxide (DMSO, 100 
l/well) was added to dissolve the precipitates. The absorbance results 
were quantified at 560 nm with a plate reader (Biotek, USA). 
5.2.4 Real-time PCR 
           Total RNA was purified with RNeasy Mini Kit (Qiagen).  Reverse 
transcription was prepared with cells-to-cDNA kit (Invitrogen). Real-time 
PCR using Power SYBR Green PCR master mix (Applied Biosystems) 
was carried out in a mini Fast real-time PCR system (BIORAD) according 
to the manufacturer’s instructions. Data were analyzed using the ΔΔCt 
method with GAPDH as a housekeeping gene. The PCR reaction 
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conditions utilized include: 50 cycles of PCR, 95 o C for 15 s, 60 o C for 1 
min. The sequences of gene primers were listed as follows: 
OPN 
Forward primer, 5’- GACGGCCGAGGTGATAGCTT -3’  
Reverse primer, 5’- CATGGCTGGTCTTCCCGTTGC -3’; 
OCN 
Forward primer, 5’- AAAGCCCAGCGACTCT-3’  
Reverse primer, 5’- CTAAACGGTGGTGCCATAGAT -3’; 
SOX2 
Forward primer, 5’- GAACGCCTTCATGGTATGG -3’  
Reverse primer, 5’- AGCCGTTCATGTAGGTCTGC -3’; 
GAPDH (Housekeeping gene), 
Forward primer, 5’ -CGATCCCGCTAACATCAAAT -3’, 
Reverse primer, 5’ -GGATGCAGGGATGATGTTCT -3’. 
5.2.5 Immunofluorescence assay 
135 
 
          The MSCs on the phage films were first fixed with 4% 
paraformaldehyde for 40 min at room temperature. Then the cells were 
incubated for 1 h in a blocking buffer (5% goat serum, 1% BSA, 0.1% 
Triton X-100 in PBS). The blocking buffer was discarded and cells were 
incubated overnight at 4°C with primary antibody anti-osteocalcin (OCN) 
antibody (1:1000, Abcam) and anti-osteopontin (OPN) antibody (1:1000, 
Abcam) developed from rabbit. Phosphate-buffered saline (PBS) was then 
used to wash the sample. Cells were incubated with goat anti-rabbit IgG-
Alexa Fluor®488 (1:300, abcam) or goat anti-rabbit IgG-TRITC (1:250, 
Santa Cruz) in PBS (5% goat serum) at 37°C for 1 h. Cell nuclei were 
stained with DAPI. The samples were visualized with fluorescence 
microscope (Nikon Eclipse Ti). 
5.2.6 Mineralization assay 
           MSCs were cultured on the phage films in 96-well plates. Cells 
were fixed with 4% paraformaldehyde and mineralized nodules were 
stained with Alizarin red S for 20 min222,223.  The Alizarin Red S-calcium 
complex product was dissolved in 0.2 N sodium hydroxide and 
absorbance was measured at 548 nm on a plate reader (Biotek, USA). 
5.2.7 Propagation of phages.  
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Phage nanofibers were amplified and purified according to the protocol 
with modifications110. First, 20 µl of phage containing E. coli solution was 
added into 10 ml LB medium (20 µg/mL tetracycline) and incubated at 
37°C overnight. Next the overnight culture was introduced into 1 L LB 
medium (20 µg/mL tetracycline) and incubated for 10 h in a shaking 
incubator. The culture solution was centrifuged at 3000g for 15 min and 
then at 8200g for 15 min to remove the E. coli. 150 ml of PEG/NaCl 
solution (500 mL of water, 116.9 g of NaCl and 100 g of PEG) was added 
to the resultant clear supernatant and the mixture was kept at 4°C for 4 h. 
The phages were precipitated by centrifugation at 8200g for 1 h. 30 ml of 
Tris buffered saline (TBS) was used to re-suspend phage precipitates and 
then the suspension was centrifuged again at 11000g for 10 min. 5 ml of 
PEG/NaCl solution was added to the supernatant and kept at 4°C 
overnight. The phages were precipitated at 11000g and re-suspended in 
TBS. Phage concentration was evaluated with a spectrophotometer using 
the formula: 1 absorbance unit (AU) 269nm=6.5 ×10
12 pfu/ml. 
5.2.8 Statistical analysis.  
          Statistical analysis was performed using two-tailed unpaired 





Figure 5.1  Schematics showing phage display technique (A) and the 
construction of phage-based film through a layer-by-layer self-assembly 
technique (B). A) Display of peptides on phage: Foreign peptides (e.g 
VTAMEPGQ) were introduced to the N-terminal of the major coat protein 
of filamentous Fd phage by phage display technique. In this study, the 
engineered phage was selected from a random library by biopanning 
process. B) Assembly of phage into films: Polylysine was first deposited 
on the glass substrate, then phage nanofibers were introduced as the 
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second layer. This procedure was repeated three times to form the phage-
based films. The as-formed films were found to support the proliferation 
and differentiation of MSCs.  
5.3.1 Characterization of phage film 
The phage nanofibers were first assembled into a film by our previously 
reported layer-by-layer technique189. Schematic in Figure 5.1 shows phage 
display technique. Wild-type (WT) phage was used as a control. In the 
layer-by-layer assembly technique, the liquid crystalline phase transitions 
and interaction between negatively charged phage and positively charged 
polylysine provide driving force for the formation of highly ordered 
supramolecular phage film. The self-assembled phage film exhibited a 
rough surface made of parallel bundles (ridges) separated by grooves 
(Figure 5.2). Our study shows that phage concentration determines the size 
of the ridge/groove property. At a high phage concentration (1014 pfu/ml), 
phage formed bundles with a diameter of around 4 m (Figure 5.2). In 
comparison, phage bundles were around 2 m in diameter at a medium 
phage concentration (1013 pfu/ml). We didn’t observe phage bundle 
formation at a low phage concentration (1012 pfu/ml) under optical 
microscope.  However, we were able to monitor phage bundles under 
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transmission electron microscopy (TEM) at a concentration of 1013 pfu/ml 
and 1010 pfu/ml (Figure 5.3).  
 
  
Figure 5.2  Characterization of phage film with optical microscopy and 
SEM. The phage film was derived from phages with medium 
concentration (1013 pfu/ml) and high concentration (1014 pfu/ml). The red 
arrows indicate the width of a single phage bundle.  The phage bundles 




Figure 5.3  TEM images of phage bundles formed at different phage 
concentrations. Higher phage concentration (1013 pfu/ml) induced the 
formation of thicker and rigid phage bundles.  Lower phage concentration 
(1010 pfu/ml) resulted in the formation of thinner and flexible phage 
bundles.    
5.3.2 Morphology of rMSCs on phage films 
           We studied the rMSCs morphologies on the phage films with 
polylysine coated substrate as a control. As shown in Figure 5.4 and 
Figure 5.5, rMSCs on the films assembled from phage at a medium 
concentration (1013 pfu/ml) showed elongation and alignment along the 
phage ridges/grooves. The high magnification images of rMSCs were 
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demonstrated in Figure 5.6. MSCs on the films assembled form phage at a 
high concentration (1014 pfu/ml) demonstrated enhanced spatial elongation. 
In comparison, rMSCs on the control poly-lysine substrate exhibited 
random orientation and didn’t show elongation. On the phage substrate 
with low concentration, rMSCs exhibited random orientation, but also 
showed stretches along different directions. Cell surface areas were also 
dependent on the phage concentrations (Figure 5.7). The films derived 
from high phage concentration (1014 pfu/ml) induced significantly 
decreased cell surface areas comparing with the control polylysine 
substrates. These results demonstrated that rMSCs morphologies are 
significantly influenced by the phage concentrations. However, we didn’t 
observe significant changes in rMSCs morphology on the phage films with 




Figure 5.4  Scanning electron microscopy (SEM) analysis showing the 
effects of phage concentrations on the morphology of MSCs cultured for 
five days. Con: polylysine coating. Low: phage films assembled from 
phage at a low concentration (1010 pfu/ml). Medium: phage films 
assembled from phage at a medium concentration (1013 pfu/ml). High: 
phage films assembled from phage at a high concentration (1014 pfu/ml). 
MSCs show alignment and elongation on the phage films derived from the 





Figure 5.5  Bright-field images showing the morphology of live MSCs 
cultured for three days and fluorescence images showing the morphology 
of stained MSCs cultured for five days on control and phage substrates. 
Phage substrates are the phage films prepared with a concentration of 1013 
pfu/ml. Control (Con) substrates are the polylysine-coated plates. Cell 
nuclei were stained with DAPI (blue). F-actin was stained with FITC-




Figure 5.6  (A-C) SEM images at different magnifications showing 
rMSCs adhesion to phage bundles generated from VT-Phage (5×1013 
pfu/ml). B) High magnification inset region in red box of image A. C) 
Higher magnification of the region in red box in image B. Red arrows 






Figure 5.7  MSCs surface areas on the phage films generated from 
different phage concentrations. Data were normalized to cells grown on 
control (Con) polylysine coated substrates. Asterisk denotes p< 0.05 when 
compared with control.   
5.3.3 Proliferation of rMSCs on phage film 
           We proceeded to investigate rMSCs proliferation on the phage 
films with different concentrations and displayed peptide motifs (Figure 
5.8). 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) proliferation assay demonstrated that rMSCs proliferation was 
regulated by both the concentrations of phages and the peptide motifs 
displayed on the phage nanofibers. As the concentration of WT-phage 
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increased, the rMSCs proliferation rate decreased (Figure 5.8a). rMSCs 
seeded on the VT-phage film demonstrated higher proliferation rate than 
those on AF, DT or WT-phage films (Figure 5.8b). There is no significant 
difference between the growth rate of MSCs on AF, DT or WT-phage film.  
 
Figure 5.8  MSCs proliferation on the phage films assembled from phage 
at different concentrations (a) or displaying different peptide motifs (b). a) 
MSCs were seeded on the wild-type phage films assembled from phages 
of a low concentration (1010 pfu/ml), medium concentration (1013 pfu/ml), 
and high concentration (1014 pfu/ml). Polylysine-coated substrate was 
used as a control. Asterisk denotes p< 0.05 when a group was compared 
with the control, n = 3. b) MSCs grown on the phage film (1013 pfu/ml) 
displaying various peptide sequences . VT, AF, and DT denoted films 
assembled from phage displaying VTAMEPGQ, AFNPEPGQ, and 
DTPPGWDQ, respectively. WT denoted films assembled from wild-type 
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phage. Con denoted polylysine coated control substrate. Asterisk denotes 
p< 0.05 when compared with VT group, n = 3.   
5.3.4  rMSCs differentiation on phage films 
           To investigate how these phage-displayed peptide sequences 
regulate rMSCs differentiation, we employed real-time PCR to evaluate 
the osteogenic differentiation of rMSCs on the phage films (Figure 5.9). 
rMSCs were cultured in primary non-osteogenic medium for three weeks 
before the assay. Various genetic markers associated with cell 
differentiation including osteocalcin (OCN), osteopontin (OPN) and 
pluripotency sex-determining region Y-box 2 (SOX2) were evaluated. 
VT-phage significantly induced and promoted osteogenesis by up-
regulating OCN and OPN gene expression comparing with polylysine 
coated control groups (p<0.01) (Figure 5.9A). AF and DT-phage also 
demonstrated enhanced osteogenesis comparing with the control substrate 
(p<0.05). The immunofluorescence assay also demonstrated that VT-
phage induced osteogenesis with enhanced OCN and OPN protein 
expression (Figure 5.9B). For pluripotency RT-PCR assay, VT-phage 
significantly down-regulated SOX2 gene expression (Figure 5.10). This 
decreased pluripotency property indicated the enhanced differentiation of 
MSCs. The real-time PCR and immunofluorescence assay collectively 
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show a direct relationship between the rMSC-binding affinity and the 
rMSC differentiation induction capability of the peptides. 
          To further evaluate the osteogenic mineralization property of rMSCs, 
alizarin red S staining was used to detect the calcium deposit formation 
(Figure 5.9C). The calcium deposits were dissolved in sodium hydroxide 
and quantified with absorbance at 548 nm222,224 (Figure 5.9D). Our results 
indicated that VT-phage significantly induced and promoted osteoblastic 





Figure 5.9  Osteogenic differentiation of MSCs on the phage films after 
MSCs were cultured in basal media for three weeks. A) Real-time PCR 
analysis of OCN and OPN mRNA expression (n=3). B) 
Immunofluorescence assay of OCN (green) and OPN (red) expression of 
MSCs on the phage films. OCN was marked with green fluorescent Alexa 
Fluor® 488 labeled antibody. OPN was marked with red fluorescent 
tetramethylrhodamine (TRITC) labeled antibody.  Cell nuclei were stained 
with DAPI (blue). C) Alizarin red S staining of MSCs on the VT-phage 
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film and control polylysine substrate.  D) Quantitative analysis of 
mineralization of MSCs on the phages films (n=3).  * denotes p<0.05, ** 
denotes p<0.01 compared with control.  
 
Figure 5.10   Real-time PCR analysis for pluripotency marker SOX2 
mRNA expression (n=3). VT-phage down-regulated SOX2 gene 
expression when compared with control phage.  * denotes p<0.05, ** 





Figure 5.11  Schematic showing proposed mechanism of rMSCs 
differentiation induced by phage matrix. Displayed VT-peptide binds to 
BMP receptors. Specific signal transduction proteins are activated, then 
translocate to the cell nucleus and bind to DNA to regulate gene 
transcription. This results in osteogenic protein expression upregulation. 
 
Amino acid of VT-Peptide Amino acid of BMP-8A that shows 





Table 5.1  Similarity between VT-peptide and BMP-8A (protein ID: 
P34821.1) revealed by BLAST. 
Amino acid of VT-Peptide Amino acid of BMP-11 that shows 
similarity with VT-peptide 
1VTAMEPG7 269VTSLGPG275 
Table 5.2  Similarity between VT-peptide and BMP-11 (protein ID: 
Q9Z1W4.1) revealed by BLAST. 
 
5.4  Discussion 
             Peptide sequences as biochemical cues had been reported to 
influence proliferation and osteoblastic differentiation of stem cells. For 
example, osteogenic growth peptide (OGP) is a 14-amino acid peptide that 
mainly regulates proliferation, bone minerization and alkaline phosphatase 
activity225,226. OGP could bind to OGP-receptor so as to activate Gi protein 
mitogen-activated protein (MAP) kinases signaling cascade.  In the 
meantime, MAP kinase has a pivotal role in the proliferation and 
osteogenic differentiation of human MSCs225,227. Miao et al reported a 
parathyroid hormone-related peptide enhanced rat bone marrow 
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osteogenic cell proliferation through activation of the Ras/MAP kinase 
signaling pathway228. Yang et al demonstrated that RGD peptide-tethered 
biomaterial stimulated osteogenesis of bone marrow-derived marrow 
stromal cells with enhanced alkaline phosphatase and OCN expression in a 
dose-dependent fashion229. Kiessling et al identified peptides binding to 
human embryonal carcinoma cells (ECs) using phage display and then 
found that these peptides, once immobilized on gold substrates, support 
the proliferation of undifferentiated human embryonal stem cells99. 
            Our results indicate that there is a direct relationship between the 
rMSCs binding affinity of peptides identified by rMSCs and the 
osteogenic differentiation inducing capability of the rMSCs. Namely, the 
higher binding affinity results in better inducing capability of a peptide. 
VT-peptide displayed on the phage films significantly induced and 
promoted osteoblastic differentiation of rMSCs by up-regulating OCN and 
OPN gene expression, while down-regulating SOX2 gene expression. 
Other studies also showed that SOX2 down-regulation led to the loss of 
pluripotency and subsequent differentiation of MSCs230.  
            To further understand the role of these peptides in inducing the 
osteogenic differentiation of MSCs, we carried protein blast of these 
sequence on national center for biotechnology information (NCBI) 
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database. Surprisingly, we found that amino acid position 2-6 and 225-228 
of bone morphogenetic protein 8A (BMP8A), which is also known as 
osteogenic protein 2 (OP-2), are similar to the amino acid position 4-7 and 
3-7 of the VT-peptide, respectively (Table 5.1). BMP8A is a growth factor 
that induces cartilage and bone formation and plays an important role in 
bone homeostasis and calcium regulation 231,232. We also found that the 
amino acid position 1-7 of the VT-peptide is similar to the amino acid 
position 269-275 of another BMP, bone morphogenetic protein 11 
(BMP11), also known as growth differentiation factor 11 (GDF11) (Table 
5.2). It is known that BMP11 regulates axial skeletal patterning and limb 
skeletal formation 233-235. Namely, the VT-peptide shows similarity with 
two BMPs that can regulate osteogenic differentiation. Interestingly, we 
did not find any similarity between other peptides (AF and DT) and these 
two BMPs. 
           Hence, we propose that VT-peptide binds to BMP receptors to 
initiate osteogenic differentiation pathway (Figure 5.11). Specific signal 
transduction proteins are then activated and translocate to the rMSCs 
nucleus. Osteogenic transcription factors are then recruited to regulate 
gene transcription. This results in OCN and OPN protein expression 
upregulation as well as calcium deposit formation. The future goal of our 
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                              Chapter 6 
6.1 Summary of this dissertation 
Stem cells hold great potential for the regenerative medicine and 
tissue engineering. Controlled delivery of specific genes to stem cells 
presents a promising strategy to alter the differentiation fate of stem cells. 
In this thesis, we developed non-viral vectors with efficient gene delivery 
and low toxicity to hard-to-transfect MSCs. MSCs demonstrated capacity 
to differentiate into cell types including osteogenic, chondrogenic, 
myogenic and adipogenic lineages. Also, they are easy to isolate and 
demonstrated significant expansion capability. As a result, MSCs are 
promising candidates for the regenerative medicine. 
 In chapter 2, we employed phage display technique and identified a 
peptide (VTAMEPGQ) that can home to rat mesenchymal stem cells 
(rMSCs). A nanoparticle, called liposome protamine/DNA lipoplex 
(LPD), is electrostatically assembled from cationic liposomes and an 
anionic complex of protamine, DNA and targeting peptides. Various 
peptides are enveloped inside the LPD to improve its targeting capability 
for rMSCs and nuclei. The rMSC-targeting peptide and nuclear 
localization signal (NLS) peptide can execute the synergetic effect to 
promote transfection action of LPD. The homing peptide directs the LPD 
157 
 
to target the MSCs, whereas the NLS peptide directs transposon to 
accumulate into nuclei once LPD is internalized inside the cells, leading 
to increased gene expression. This suggests that rMSC-targeting peptide 
and NLS peptide within LPD can target to rMSCs and then guide 
transposon uptake into nuclei. After entering the nuclei, the SB 
transposon increases the insertion rates into cellular chromosomes. The 
targeting LPD does not show obvious cell toxicity and influence on the 
differentiation potential of rMSCs. Therefore, the integration of SB 
transposon and LPD system may represent a promising non-viral gene 
delivery vector in stem cell therapy. 
In chapter 3, we continued to improve the LPD based gene delivery 
system on rMSCs. We re-synthesized the LPD particle using a 
chemically defined faction. Also, we introduced three-folds reiterated 
targeting peptides and a vascular endothelial growth factor (VEGF) 
reporter gene. Overall, we developed a non-viral vector integrating lipids, 
sleeping beauty transposon system and 8-mer stem cell targeting peptides 
for safe and efficient gene delivery to MSCs. The 8-mer MSC-targeting 
peptides, when synthetically reiterated in three-folds and chemically 
presented on the surface, significantly promoted the resultant lipid-based 
nanoparticles (LBNs) to deliver VEGF gene into MSCs with a high 
transfection efficiency and long-lasting gene expression when compared 
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to non-reiterated peptides. However, the reiterated stem cell targeting 
peptides do not enable the highly efficient gene transfer to other control 
cells. This work suggests that the surface presentation of the reiterated 
stem cell-targeting peptides on the non-viral vectors is a promising 
method for improving the efficiency of cell-specific non-viral gene 
transfection in stem cells. 
In chapter 4, we developed a non-viral vector integrating fusogenic 
and magnetic properties for safe and efficient gene delivery to MSCs. 
Glutathione (GSH) cleavable magnetic/silica nanoclusters are synthesized, 
where magnetic nanoparticles (NPs) are dispersed in a porous silica 
matrix by S-S bond. The porous structure can hold DNA with the aid of 
polyethyleneimine (PEI), which is further conjugated with MSC-homing 
major coat protein (pVIII) purified from the MSC-homing phage 
identified by using phage display technique. Due to the presence of pVIII 
on the surface, the resultant virus mimetic magnetic silica nanoclusters 
(VMSNCs) can transfect rat MSCs in a higher efficiency than 
commercially available non-viral vectors. The intracellular GSH is 
responsible for cleaving the S-S bond to dissociate the nanoclusters to 
release DNA. The VMSNCs bear MSC-homing phage-borne protein on 




           In chapter 5, we studied the osteogenic differentiation induction of 
rMSCs by rMSC-binding peptides with different binding affinities using 
phage-based matrix. The phage-based matrix has nearly constant 
architecture but different rMSC-binding peptides, enabling us to focus on 
and reveal a direct relationship between rMSC-binding affinities and 
osteogenic differentiation induction capabilities of the peptides. 
VTAMEPGQ, with the highest rMSC-binding affinity, was verified to 
most efficiently induce the osteogenic differentiation of rMSCs. 
Surprisingly, we found that VTAMEPGQ peptide shares good similarity 
in sequence with two BMPs. This result encourages us to hypothesize that 
the peptide binds to BMP receptor to initiate the osteogenic differentiation 
pathway.   
    In summary, first we discovered MSCs-targeting peptide 
sequence. Then we developed non-viral MSCs-targeting gene delivery 
vector with high gene transfection efficiency and sustained gene 
expression profile using the MSCs-targeting peptide or MSCs-targeting 
phage protein. We also discovered that the peptide (VTAMEPGQ) 
induced the osteogenic differentiation of MSCs efficiently. These specific 
targeting complexes may demonstrate promising applications in clinical 
stem cell-based therapy.  
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